Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer

array:24 ["pii" => "S1807593222012960" "issn" => "18075932" "doi" => "10.6061/clinics/2016(01)03" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "1296" "copyright" => "CLINICS" "copyrightAnyo" => "2016" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by/4.0/" "subdocumento" => "fla" "cita" => "Clinics. 2016;71:10-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S1807593222012972" "issn" => "18075932" "doi" => "10.6061/clinics/2016(01)04" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "1297" "copyright" => "CLINICS" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by/4.0/" "subdocumento" => "fla" "cita" => "Clinics. 2016;71:17-21" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "CLINICAL SCIENCE" "titulo" => "Severe potential drug-drug interactions in older adults with dementia and associated factors" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "17" "paginaFinal" => "21" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Michele Bogetti-Salazar, Cesar González-González, Teresa Juárez-Cedillo, Sergio Sánchez-García, Oscar Rosas-Carrasco" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Michele" "apellidos" => "Bogetti-Salazar" ] 1 => array:2 [ "nombre" => "Cesar" "apellidos" => "González-González" ] 2 => array:2 [ "nombre" => "Teresa" "apellidos" => "Juárez-Cedillo" ] 3 => array:2 [ "nombre" => "Sergio" "apellidos" => "Sánchez-García" ] 4 => array:2 [ "nombre" => "Oscar" "apellidos" => "Rosas-Carrasco" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222012972?idApp=UINPBA00004N" "url" => "/18075932/0000007100000001/v1_202211290914/S1807593222012972/v1_202211290914/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1807593222012959" "issn" => "18075932" "doi" => "10.6061/clinics/2016(01)02" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "1295" "copyright" => "CLINICS" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by/4.0/" "subdocumento" => "fla" "cita" => "Clinics. 2016;71:5-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "CLINICAL SCIENCE" "titulo" => "Eszopiclone versus zopiclone in the treatment of insomnia" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "5" "paginaFinal" => "9" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Luciano Ribeiro Pinto, Lia Rita Azeredo Bittencourt, Erika Cristine Treptow, Luciano Rotella Braga, Sergio Tufik" "autores" => array:5 [ 0 => array:3 [ "nombre" => "Luciano Ribeiro" "apellidos" => "Pinto" "sufijo" => "Jr" ] 1 => array:2 [ "nombre" => "Lia Rita Azeredo" "apellidos" => "Bittencourt" ] 2 => array:2 [ "nombre" => "Erika Cristine" "apellidos" => "Treptow" ] 3 => array:2 [ "nombre" => "Luciano Rotella" "apellidos" => "Braga" ] 4 => array:2 [ "nombre" => "Sergio" "apellidos" => "Tufik" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222012959?idApp=UINPBA00004N" "url" => "/18075932/0000007100000001/v1_202211290914/S1807593222012959/v1_202211290914/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "CLINICAL SCIENCE" "titulo" => "Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "10" "paginaFinal" => "16" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Qian Zhou, Cheng Tang, Ke-Wei Zhao, Yan-Li Xiong, Shu Chen, Wen-Jing Xu, Xin Lei" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Qian" "apellidos" => "Zhou" ] 1 => array:1 [ "apellidos" => "Cheng Tang" ] 2 => array:2 [ "nombre" => "Ke-Wei" "apellidos" => "Zhao" ] 3 => array:2 [ "nombre" => "Yan-Li" "apellidos" => "Xiong" ] 4 => array:2 [ "nombre" => "Shu" "apellidos" => "Chen" ] 5 => array:2 [ "nombre" => "Wen-Jing" "apellidos" => "Xu" ] 6 => array:4 [ "nombre" => "Xin" "apellidos" => "Lei" "email" => array:1 [ 0 => "dpxinlei@126.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Third Military Medical University, Cancer Center, Research Institute of Surgery and Daping Hospital, Chongqing, China" "identificador" => "aff1" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "corresponding author" ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig2" "etiqueta" => "Figure 2-" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 599 "Ancho" => 648 "Tamanyo" => 50571 ] ] "descripcion" => array:1 [ "en" => "Isodose contour showing that the dose at point F was nearly identical to that at point A in stage II and III patients. A and F denote dose reference points A and F, respectively. The cervix is indicated by arrows and the uterus is indicated by curled arrows." ] ] ] "textoCompleto" => "INTRODUCTIONEndometrial cancer is one of the most common gynecologic malignancies worldwide. According to a report from the American Cancer Society, approximately 52,630 new cases of endometrial cancer were diagnosed and 8,590 deaths were associated with endometrial cancer in the United States in 2014 <a class="elsevierStyleCrossRef" href="#bib1">1</a>. The National Cancer Institute of China estimated that there would be 47,751 new cases of endometrial cancer in China in 2010 <a class="elsevierStyleCrossRef" href="#bib2">2</a>. Currently, surgery remains the standard treatment for early-stage endometrial cancer. However, radiation has become a more suitable treatment option for patients with medically inoperable endometrial cancer or for those of advanced age.In terms of a definitive radiotherapy for endometrial cancer, intracavitary brachytherapy (ICBT) alone can be used to treat stage I patients. Moreover, ICBT combined with external beam radiotherapy (EBRT) can be used to treat patients with local advanced-stage endometrial cancer. Generally, there are two types of brachytherapy using conventional γ-rays: high-dose-rate (HDR) brachytherapy using 192Ir or low-dose-rate (LDR) brachytherapy using 137Cs. There have been no randomized controlled trials (RCT) comparing the effects of HDR brachytherapy and LDR brachytherapy on endometrial cancer in recent years because endometrial cancer is rarely treated with radiotherapy alone <a class="elsevierStyleCrossRef" href="#bib3">3</a>,<a class="elsevierStyleCrossRef" href="#bib4">4</a>.Many reports in the literature have described the use of californium-252 (252Cf) as a neutron source for the treatment of cervical cancer due to its higher relative biologic effectiveness (RBE) and lower oxygen enhancement rate (OER) than γ-rays <a class="elsevierStyleCrossRef" href="#bib5">5</a>,<a class="elsevierStyleCrossRef" href="#bib6">6</a>. Moreover, the 252Cf neutron source has been used effectively for ICBT of endometrial cancer <a class="elsevierStyleCrossRef" href="#bib7">7</a>. However, a single-channel applicator was used in most endometrial cancer studies <a class="elsevierStyleCrossRef" href="#bib8">8</a>,<a class="elsevierStyleCrossRef" href="#bib9">9</a>, including our own, which is described below <a class="elsevierStyleCrossRef" href="#bib10">10</a>. The use of a single-channel applicator has several drawbacks, including longer treatment durations and a slightly higher incidence of complications than the use of a two-channel applicator <a class="elsevierStyleCrossRef" href="#bib9">9</a>. Further, the dose distribution associated with a single-channel applicator is not ideal and is difficult to adjust. Between 1999 and 2004, our center performed 252Cf neutron ICBT using a single-channel applicator to treat 40 cases of endometrial cancer and we observed the above-described shortcomings associated with this method (i.e., long treatment durations, a high rate of complications and difficulty in adjusting the dose and the dose distribution).The modification of two-channel (TC) Y (Rotte Y) applicators for brachytherapy has overcome many of the shortcomings associated with single-channel applicators, particularly with regard to adjustment of the optimal dose distribution in the craniocaudal and lateral directions. Therefore, TC applicators have become the standard fixed applicators used for γ-ray ICBT of endometrial cancer <a class="elsevierStyleCrossRef" href="#bib11">11</a>.In 2007, our center began employing a 252Cf neutron source using the TC applicator for endometrial cancer treatment. The aim of this study was to assess the clinical outcomes of endometrial cancer patients treated via 252Cf neutron ICBT using a TC applicator combined with EBRT.MATERIALS AND METHODSSubjectsThirty-one stage I–III endometrial cancer patients diagnosed based on biopsy findings and staged according to the International Federation of Gynecology and Obstetrics (FIGO) guidelines from September 2007 to August 2011 were included in this study. Among these patients, the most common comorbidities associated with receiving radiotherapy alone included hypertension and diabetes (<a class="elsevierStyleCrossRef" href="#tbl1">Table 1</a>). None of the patients had received treatment before the study, and all endometrial cancer diagnoses had been confirmed by histology. All of the patients exhibited Karnofsky scores greater than 70 and hemoglobin levels greater than 90 g/L; their mean age was 55.9 years (range: 30–72 years) (<a class="elsevierStyleCrossRef" href="#tbl1">Table 1</a>).<elsevierMultimedia ident="tbl1"></elsevierMultimedia>All of the patients underwent a chest x-ray, an abdominal B-ultrasound, a pelvic CT or MRI, cystoscopy and a colonoscopy as components of their pre-treatment evaluation. During the course of treatment, a pelvic B-ultrasound and a gynecological examination were performed every week to examine changes in uterine size and uterine cavity depth.Treatment methodsEquipmentAn LZH-1000 252Cf neutron brachytherapy machine (Shenzhen Lingdun Technology, Shenzhen, China) and an 8 MV/X linear accelerator (Elekta Corp., Stockholm, Sweden) were used. For the 252Cf neutron source, the average energy was 2.3 MeV, with a half-life of 2.645 years; the shape was cylindrical with dimensions of 3 mm in diameter × 8 mm in height, an active region of 1.4 mm × 9.0 mm, and a source strength per unit volume of 500–200 μg. The following formula was used to calculate the 252Cf dose: equivalent biological dose (DGY-eq) = neutron relative biological effectiveness (RBE) of 252Cf × 252Cf neutron dose + γ-ray RBE x γ-ray dose; the 252Cf RBE ranged from between 4–6.Treatment planStage I patients underwent 252Cf neutron ICBT using the TC applicator alone. Stage II or III patients underwent 252Cf neutron ICBT using the TC applicator combined with EBRT. All patients were hospitalized throughout the treatment period. External radiation was applied four times per week with opposing fields and a dose per fraction of 2 Gy. Once the total dose reached 20–36 Gy in 10–18 fractions, the central portion of the field was shielded using a 4 cm thick lead block, and the treatment was continued with antero-posterior field irradiation until the total dose reached 46–50 Gy. 252Cf neutron ICBT using the TC applicator was delivered after 4–5 fractions of EBRT. ICBT then continued once per week, with the EBRT applied on 4 other days of the week. The total treatment duration was 6-7 weeks. A non-steroidal painkiller or morphine was administered before applicator placement. Barium enemas and bladder catheterizations were prepared prior to injection of the contrast agent into the balloon. Then, between 7 and 12 cervical dilatation rods were used sequentially to gradually expand the cervix until it was sufficiently enlarged. The two channels of the applicator were turned to a vertical position such that the two front ends were closed together, followed by insertion of the fundus was inserted into the uterus. The TC applicator was then turned to the horizontal position such that the top of the two channels reached the two horns of the uterus, and an anterolateral image was captured (<a class="elsevierStyleCrossRef" href="#fig1">Figure 1</a>). Points A and F (point F was defined on line A, 2 cm lateral to the top of the TC applicator) were chosen as the dose reference points. The brachytherapy dose was 40–45 Gy to point A and 48–55 Gy to point F in 4–5 fractions. For stage I patients, the dose at point F was higher than that at point A. For stage II or III patients, the dose at point F was approximately the same as that at point A (<a class="elsevierStyleCrossRef" href="#fig2">Figure 2</a>). The dose at the posterior wall of the bladder and the rectum was adjusted based on the isodose contour so that the dose at the bladder and the rectum was below 80% of that at point A. Stage I or II patients were administered a single channel and a vault tube of internal irradiation (<a class="elsevierStyleCrossRef" href="#fig3">Figure 3</a>) to supplement potentially insufficient doses at the uterine fundus and the vaginal fornix. The ratio of the dose applied to the cervix to the dose applied to the vaginal fornix was 1.0:(0.8–1.0) for stage I patients (<a class="elsevierStyleCrossRef" href="#fig4">Figure 4</a>) and 1.0:(1.2–1.4) for stage II patients (<a class="elsevierStyleCrossRef" href="#fig5">Figure 5</a>). During 252Cf neutron ICBT using the TC applicator, the patients were monitored for symptom alleviation, and gynecological examinations were performed weekly to determine the size of the uterus and the extent of tumor regression. At six months post-treatment, uterine curettage and histopathological examination were performed to examine tumor cell regression.<elsevierMultimedia ident="fig1"></elsevierMultimedia><elsevierMultimedia ident="fig2"></elsevierMultimedia><elsevierMultimedia ident="fig3"></elsevierMultimedia><elsevierMultimedia ident="fig4"></elsevierMultimedia><elsevierMultimedia ident="fig5"></elsevierMultimedia>Follow-upsBeginning one month post-treatment, a pelvic B-ultrasound was performed monthly. At three months post-treatment, uterine curettage and histopathological examination of the endometrial tissues were performed. Outpatient follow-up visits were required once every three months beginning three months post-treatment and once every six months beginning one year post-treatment. None of the patients were lost to follow-up.Statistical analysisSPSS13.0 software was used for statistical analyses. Discrete data are presented as frequencies (percentages); continuous data are presented as means ± SE. For statistical analyses, Chi-square contingency table analysis and Kaplan-Meier tests were performed; p-values<0.05 were considered statistically significant (<a class="elsevierStyleCrossRefs" href="#tbl2">Tables 2 and 3</a>).<elsevierMultimedia ident="tbl2"></elsevierMultimedia><elsevierMultimedia ident="tbl3"></elsevierMultimedia>EthicsThis study was approved by the ethics committee of our hospital, and all patients signed informed consent forms.RESULTSThe mean follow-up duration was 54.8 months. Of the 31 patients enrolled in this study, 15 patients died during the follow-up period. One of the stage I patients died as a result of fatal coronary artery disease. Two stage III patients died from the persistent tumor. Three deceased patients had pelvic lymph node recurrence, four deceased patients had local recurrence at the time of death, and five deceased patients had distant metastases. The mean overall survival duration was 61.8±5.2 months, with a 95% confidence interval of 51.6–72.0 months (<a class="elsevierStyleCrossRef" href="#tbl3">Table 3</a>). The 5-year overall survival rate for all patients was 51.6% (<a class="elsevierStyleCrossRef" href="#fig6">Figure 6</a>). The disease-specific survival (DSS) rates for stages I, II, and III were 100%, 54.5%, and 0%, respectively (<a class="elsevierStyleCrossRef" href="#tbl2">Table 2</a>).<elsevierMultimedia ident="fig6"></elsevierMultimedia>Following treatment via 252Cf neutron ICBT using the TC applicator combined with EBRT, both pelvic B-ultrasound and gynecological examination showed that the uterus had shrunk substantially in all 31 patients and that the uterine cavity depth was reduced to a varying extent (0.5–5.0 cm). Of the two locally uncontrolled patients treated with an additional fraction of 252Cf neutron ICBT using the TC applicator, one experienced locally controlled disease, and the other, who showed clear cell histology, experienced local failure. The most common locations of disease recurrence were distant (16.1%), local recurrence alone (12.9%), and pelvic lymph nodes (9.6%). Of the five patients with distant tumor recurrence, three exhibited a single distant tumor involving the lungs and bone, and two exhibited multi-organ involvement. Additionally, patients with comorbid endometrial cancer and diabetes were more susceptible to metastasis development and disease recurrence (8/31) (<a class="elsevierStyleCrossRef" href="#tbl4">Table 4</a>).<elsevierMultimedia ident="tbl4"></elsevierMultimedia>All patients completed the treatment without interruption. All of the late complications were limited to grade 2, and there were no recto-vaginal or vesico-vaginal fistulas. Three patients had frequent urination, urgency, and hematuria at 26 months post-radiotherapy. Cystoscopic examination ruled out other diseases, and these patients were diagnosed with radiation cystitis. Another patient was diagnosed with radiation proctitis. The incidence of late complications was 12.9% (4/31) (<a class="elsevierStyleCrossRef" href="#tbl5">Table 5</a>).<elsevierMultimedia ident="tbl5"></elsevierMultimedia>DISCUSSIONSurgery remains the primary standard treatment for patients with endometrial cancer. Definitive radiotherapy is typically offered to patients who suffer from medical comorbidities and those who have locally advanced tumors, as surgery may be not suitable for these patients. Therefore, patients treated via radiotherapy have a higher mortality rate than those treated via surgery. Nevertheless, radiotherapy remains the best option for patients with inoperable endometrial cancer. Thus, comparisons of survival between surgery and radiotherapy alone are of limited value. Patients with inoperable endometrial cancer are generally treated via ICBT alone or in combination with EBRT.The most common histological type of endometrial cancer is adenocarcinoma, which is not as sensitive to conventional radiation as squamous cell carcinoma. Moreover, locally advanced stage endometrial tumors are often bulky and contain many hypoxic cells, which are resistant to conventional radiation. In contrast to conventional radioisotopes, the 252Cf neutron represents a high linear energy transfer (LET) ray with distinct radiation and biological characteristics. For example, the 252Cf neutron can cause greater direct damage to tumor cell DNA, leading to a higher rate of DNA double-strand breaks, than conventional photon radiation. The 252Cf neutron also has a higher RBE and a lower OER than photons <a class="elsevierStyleCrossRef" href="#bib7">7</a>. Thus, bulky endometrial adenocarcinoma cells may be particularly sensitive to 252Cf neutrons, and this form of radiotherapy could be used to treat endometrial adenocarcinoma patients.However, 252Cf neutron ICBT has not been the main method of choice for endometrial cancer because the neutron source used for ICBT is large and expensive and because it is difficult to achieve precise biological equivalent dose calibration using conventional γ-rays. Thus, 192Ir and 137Cs ICBT are the most commonly used forms of ICBT worldwide, especially in Western Europe and North America. Moreover, the 252Cf neutron source used for ICBT was a neutron TC applicator that was larger than the γ-ray TC applicator. Dilatation of the cervix and the uterus is required to insert the TC applicator. In general, all of the endometrial cancer patients in our study tolerated TC applicator implantation well. Patients with late toxicity to radiotherapy in our study had grade 2 complications and were diagnosed with radiation proctitis or radiation cystitis.Patients with locally advanced stage endometrial adenocarcinoma or with inoperable endometrial adenocarcinoma who are treated via a combination of γ-ray ICBT and EBRT often suffer from local-regional relapse. In the past two decades, the local control rate for patients with locally advanced stage endometrial adenocarcinoma has remained unsatisfactory, even when a salvage radical hysterectomy was performed. The local control rate was 76–84% for stage I–III endometrial adenocarcinoma patients treated via a combination of γ-ray ICBT and EBRT. Alternatively, 252Cf neutron ICBT has been found to be effective as a radiotherapy and to have radiobiological advantages for the treatment of radio-resistant advanced or bulky endometrial tumors <a class="elsevierStyleCrossRef" href="#bib7">7</a>. Our data showed that the local control rate for stage I–III endometrial adenocarcinoma patients was 80.6%. However, the local relapse rate of patients with stage I–II disease was 14.8% (4/27), and that of patients with stage III disease was 50%.The selection of an applicator is also important for ICBT of endometrial adenocarcinoma. The TC “Y” applicator consists of two rigid applicators, which can reach the two uterine horns, permitting coverage of a greater uterine width than a single-channel applicator. The dose distribution of the TC applicator was more optimal than that of the single-channel applicator, such that a satisfactory local control rate might be more effectively achieved using the TC for ICBT of endometrial adenocarcinoma. However, few studies have examined the application of the “Y” applicator for treating endometrial cancer. Ohkubo et al. reported a satisfactory local control rate in ten patients with stage I–II endometrial cancer, none of whom suffered from local recurrence at five years <a class="elsevierStyleCrossRef" href="#bib12">12</a>. The same TC applicator was used by Coon et al. to treat 49 endometrial cancer patients (most of whom had stage I disease) via HDR ICBT; in that study, three patients (6.1%) experienced local failure and the median time to disease recurrence was 17 months. These two studies showing low rates of local recurrence further show that the radiation doses were sufficient for destroying the tumor in the uterus.Differences in tumor stages and differential tumor grades are associated with distinct outcomes of endometrial cancer patients. Without question, higher tumor stage, lower differential tumor grade, and unfavorable tumor histological type are associated with poorer prognosis. Previous studies had shown that the five-year overall survival rates of stage I–III endometrial cancer patients treated via either 137Cs or 192Ir ICBT, with or without EBRT 1-5<a class="elsevierStyleCrossRef" href="#bib9">9</a>,. In contrast, in the study by Maruyama et al., 252Cf neutron ICBT combined with EBRT and hysterectomy resulted in five-year overall survival rates of 83% for stage I, 37% for stage II, and 50% for stage III endometrial cancer patients <a class="elsevierStyleCrossRef" href="#bib7">7</a>. Our current data showed a five-year overall survival rate of 51.6%; this result is consistent with other results of LDR and HDR studies, although it is lower than that from the study by Maruyama et al. We speculate that the primary reason for the higher survival rate in the study by Maruyama et al. was that nearly half of the patients (14/31) in that study underwent a hysterectomy after receiving radiation therapy; the survival rate of 50% for stage III patients in that study was much higher than that in a previous report, which showed a survival rate of only 17.5% among those undergoing radiotherapy alone <a class="elsevierStyleCrossRef" href="#bib17">17</a>.Treatment via 252Cf neutron ICBT combined with EBRT as performed in our study may be sufficient for patients with stage I–II endometrial cancer, as these patients showed a five-year overall survival rate of 59.3%. This survival rate is comparable to previous reports showing overall survival rates of 42–61% for stage I–II endometrial cancer patients <a class="elsevierStyleCrossRefs" href="#bib18">18–21</a>. Our treatment outcomes for the four patients with stage III endometrial cancer showed an unsatisfactory mean survival duration of 15.3±6.0 months. Two stage III patients died with persistent tumors. Regarding the other two stage III patients, one died 20 months post-treatment due to lung metastasis, and the other exhibited pelvic lymph node recurrence at 30 months of follow-up. These findings suggest that alternative treatment strategies should be used for patients with stage III endometrial cancer.In the course of using the “Y” applicator to treat endometrial cancer, two ovoids or a ring applicator and a single-channel applicator should be added to supplement the radiation dose to the vaginal vault; such a treatment generally increases the radiation dose to the bladder and the rectum. In fact, we observed late toxicity of grade 2 in 12.9% (4/31) of the patients; this frequency is similar to the results from most studies of stage I–III patients (<a class="elsevierStyleCrossRef" href="#tbl6">Table 6</a>). However, a study of 36 stage I patients by Nguyen et al. using one tandem and one ovoid or cylindrical applicator to perform HDR ICBT alone showed a frequency of late toxicity of up to 21% 6<a class="elsevierStyleCrossRef" href="#bib22">22</a>.<elsevierMultimedia ident="tbl6"></elsevierMultimedia>Although much effort has been invested to identify more effective methods for ICBT of endometrial cancer, no completely satisfactory method has been established. Our retrospective study contains several limitations, including the accuracy of cancer diagnosis and staging, the socioeconomic status of the patients, advances in treatment, and nurse-led supportive care. In particular, we used 2-D treatment planning, which is not as effective as 3-D planning for reducing the dose to at-risk organs <a class="elsevierStyleCrossRef" href="#bib23">23</a>.252Cf neutron ICBT using a TC applicator combined with EBRT is effective for the treatment of endometrial cancer, and the incidence of serious late complications related to this therapy is acceptable.AUTHORS CONTRIBUTIONZhou Q participated in patients care, wrote the first draft of the manuscript and performed the literature review. Tang C, Lei X were responsible for the patient care, study design, draft of the manuscript and intellectual inputs. Zhao KW, Jia L, Shan JL, Xiong YL, Chen S, Xu Wen-Jing were responsible for data collection, data analysis and manuscript writing. All authors read and approved the final version of the manuscript." "textoCompletoSecciones" => array:1 [ "secciones" => array:8 [ 0 => array:2 [ "identificador" => "xpalclavsec1580181" "titulo" => "KEYWORDS" ] 1 => array:2 [ "identificador" => "cesec10" "titulo" => "INTRODUCTION" ] 2 => array:3 [ "identificador" => "cesec20" "titulo" => "MATERIALS AND METHODS" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "cesec30" "titulo" => "Subjects" ] 1 => array:3 [ "identificador" => "cesec40" "titulo" => "Treatment methods" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "cesec50" "titulo" => "Equipment" ] 1 => array:2 [ "identificador" => "cesec60" "titulo" => "Treatment plan" ] 2 => array:2 [ "identificador" => "cesec70" "titulo" => "Follow-ups" ] 3 => array:2 [ "identificador" => "cesec80" "titulo" => "Statistical analysis" ] 4 => array:2 [ "identificador" => "cesec90" "titulo" => "Ethics" ] ] ] ] ] 3 => array:2 [ "identificador" => "cesec100" "titulo" => "RESULTS" ] 4 => array:2 [ "identificador" => "cesec110" "titulo" => "DISCUSSION" ] 5 => array:2 [ "identificador" => "cesec120" "titulo" => "AUTHORS CONTRIBUTION" ] 6 => array:2 [ "identificador" => "xack638157" "titulo" => "ACKNOWLEDGMENTS" ] 7 => array:1 [ "titulo" => "REFERENCES" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-07-07" "fechaAceptado" => "2015-11-09" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "KEYWORDS" "identificador" => "xpalclavsec1580181" "palabras" => array:3 [ 0 => "Endometrial Cancer" 1 => "Californium" 2 => "Two-Channel Y Applicator" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:2 [ "resumen" => "OBJECTIVE:The aim of this study was to determine the efficacy of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for the treatment of endometrial cancer. METHODS:Thirty-one patients with stage I–III endometrial cancer were recruited for this study. The stage I patients received only 252Californium neutron intracavitary brachytherapy with a two-channel applicator. The stage II and III patients received both 252Californium neutron intracavitary brachytherapy using a two-channel applicator and parallel-opposed whole pelvic radiotherapy. RESULTS:The five-year local control rate was 80.6% (25/31), the overall survival rate was 51.6% (16/31), and the disease-free survival rate was 54.8% (17/31). The incidence of serious late complications was 12.9% (4/31). CONCLUSIONS:252Californium neutron intracavitary brachytherapy using a two-channel applicator combined with external beam radiotherapy was effective for treating endometrial cancer and the incidence of serious late complications related to this combination was within an acceptable range." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "ceabs10" "titulo" => "OBJECTIVE:" ] 1 => array:2 [ "identificador" => "ceabs20" "titulo" => "METHODS:" ] 2 => array:2 [ "identificador" => "ceabs30" "titulo" => "RESULTS:" ] 3 => array:2 [ "identificador" => "ceabs40" "titulo" => "CONCLUSIONS:" ] ] ] ] "NotaPie" => array:1 [ 0 => array:1 [ "nota" => "No potential conflict of interest was reported." ] ] "multimedia" => array:12 [ 0 => array:7 [ "identificador" => "fig1" "etiqueta" => "Figure 1-" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 446 "Ancho" => 800 "Tamanyo" => 36147 ] ] "descripcion" => array:1 [ "en" => "A) Antero-posterior view; B) anterolateral view. The anterolateral image was captured when the TC applicator was turned to the horizontal position; this image shows that the top of the two channels reached the two horns of the uterus. A and F denote dose reference points A and F, respectively. The cervix is indicated by arrows, and the uterus is indicated by curled arrows." ] ] 1 => array:7 [ "identificador" => "fig2" "etiqueta" => "Figure 2-" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 599 "Ancho" => 648 "Tamanyo" => 50571 ] ] "descripcion" => array:1 [ "en" => "Isodose contour showing that the dose at point F was nearly identical to that at point A in stage II and III patients. A and F denote dose reference points A and F, respectively. The cervix is indicated by arrows and the uterus is indicated by curled arrows." ] ] 2 => array:7 [ "identificador" => "fig3" "etiqueta" => "Figure 3-" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 877 "Ancho" => 780 "Tamanyo" => 29811 ] ] "descripcion" => array:1 [ "en" => "Image showing the method by which stage I and II endometrial cancer patients were administered a single channel and a vault tube of internal irradiation to supplement potentially insufficient doses at the uterine fundus and the vaginal fornix. A and F denote dose reference points A and F, respectively. The cervix is indicated by arrows, and the uterus is indicated by curled arrows." ] ] 3 => array:7 [ "identificador" => "fig4" "etiqueta" => "Figure 4-" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 635 "Ancho" => 650 "Tamanyo" => 62138 ] ] "descripcion" => array:1 [ "en" => "Isodose contour showing that the ratio of the dose applied to the cervix to the dose applied to the vaginal fornix was 1.0:(0.8–1.0) in stage I patients. A and F denote dose reference points A and F, respectively. The cervix is indicated by arrows, and the uterus is indicated by curled arrows." ] ] 4 => array:7 [ "identificador" => "fig5" "etiqueta" => "Figure 5-" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 624 "Ancho" => 648 "Tamanyo" => 52981 ] ] "descripcion" => array:1 [ "en" => "Isodose contour showing that the ratio of the dose applied to the cervix to the dose applied to the vaginal fornix was 1.0:(1.2–1.4) in stage II patients. A and F denote dose reference points A and F, respectively. The cervix is indicated by arrows, and the uterus is indicated by curled arrows." ] ] 5 => array:7 [ "identificador" => "fig6" "etiqueta" => "Figure 6-" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr6.jpeg" "Alto" => 522 "Ancho" => 650 "Tamanyo" => 23917 ] ] "descripcion" => array:1 [ "en" => "Survival curves of patients with different stages of endometrial cancer." ] ] 6 => array:7 [ "identificador" => "tbl1" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Characteristics \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Number of patients (%)<a class="elsevierStyleCrossRef" href="#tfn1">*</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Total number of patients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">31 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Age (y) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">30–50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">5 (16.0%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">51–60 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">18 (58.0%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">61–72 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">8 (26.0%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Mean \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">55.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">BMI (kg/m2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Mean \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">27 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Range \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">20–41 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Stage (FIGO) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">I \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">5 (16.0%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">22 (71.0%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">4 (13.0%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Morphology \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Adenocarcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">28 (90.0%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Clear cell carcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">3 (10.0%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Histopathologic grade \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">11 (35.5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">13 (41.9%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">5 (16.1%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">2 (6.5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Comorbid diseases \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Hypertension \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">11 (35.5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Diabetes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">11 (35.5%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Coronary artery disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">3 (9.7%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Systemic lupus erythematosus \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">2 (6.4%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Others<a class="elsevierStyleCrossRef" href="#tfn2">**</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">4 (12.9%) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tfn1" "etiqueta" => "*" "nota" => "Thirty-one patients were enrolled in the study." ] 1 => array:3 [ "identificador" => "tfn2" "etiqueta" => "**" "nota" => "Others included refusal of surgery or severe chronic obstructive pulmonary disease." ] ] ] "descripcion" => array:1 [ "en" => "Patient characteristics." ] ] 7 => array:7 [ "identificador" => "tbl2" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "No.: number of patients; LCR: local control rate; OS: overall survival; DSS: disease-specific survival." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Stage \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">No. \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">LCR \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">OS \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">DSS \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Late toxicity \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">I \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">100% (5/5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">80.0% (4/5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">100% (5/5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">0% (0/5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">81.8% (18/22) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">54.5% (12/22) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">54.5% (12/22) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">18.2% (4/22) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">50.0% (2/4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">0% (0/4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">0% (0/4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">0% (0/4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">31 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">80.6% (25/31) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">51.6% (16/31) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">54.8% (17/31) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">12.9% (4/31) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">X2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">3.026 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">5.510 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">8.496 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">0.961 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">P \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">0.066 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">0.037 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">0.004 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">0.378 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "Outcomes of endometrial cancer treated via 252Cf neutron intracavitary brachytherapy." ] ] 8 => array:7 [ "identificador" => "tbl3" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "SE: standard error; CI: confidential interval.Mean overall survival duration=61.8±5.2 months (95% confidence interval, 5–85 months), X2=31.0, and p=0.000." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">FIGO stage \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Mean±SE \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">95% CI \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Median±SE \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">95% CI \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">I \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">72.0±2.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">(66.7,77.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">66.5±5.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">(56.0,77.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">85.0±13.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">(59.4, 110.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">15.3±6.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">(3.50, 27.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">6.00±7.50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">(0.00, 20.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">61.8±5.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">(51.6, 72.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">73.0±6.79 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">(59.9, 86.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "Overall survival duration of endometrial cancer patients receiving 252Cf neutron intracavitary brachytherapy." ] ] 9 => array:7 [ "identificador" => "tbl4" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "COPD: chronic obstructive pulmonary disease; SLE: systemic lupus erythematosus." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Site \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Number \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Morphology \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Number \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Comorbid diseases \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Number \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Local recurrence alone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">4 (12.9%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Adenocarcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">4 (12.9%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Hypertension Diabetes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">2 (6.4%) 2 (6.4%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Pelvic lymph node \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">3 (9.6%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Adenocarcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">3 (9.6%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Diabetes COPD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">2 (6.4%) 1 (3.2%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Persistent \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">2 (6.4%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Adenocarcinoma Clear cell carcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">1 (3.2%) 1 (3.2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Diabetes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">2 (6.4%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Distant \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">5 (16.1%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Lung \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">2 (6.4%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Adenocarcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">2 (6.4%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Hypertension Diabetes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">1 (3.2%) 1 (3.2%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Multi-organ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">2 (6.4%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Adenocarcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">2 (6.4%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Hypertension SLE \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">1 (3.2%) 1 (3.2%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Bone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">1 (3.2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Adenocarcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">1 (3.2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Diabetes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">1 (3.2%) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "The relationships of morphology and comorbid diseases with metastasis development and disease recurrence." ] ] 10 => array:7 [ "identificador" => "tbl5" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Site \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Number of grade II complications (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Cystitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">3 (9.6%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Rectum \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="top">1 (3.2%) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "Late toxicity." ] ] 11 => array:7 [ "identificador" => "tbl6" "etiqueta" => "Table 6" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "OS: overall survival; LDRB: low-dose-rate brachytherapy; HDRB: high-dose-rate brachytherapy; EBRT: external beam radiation therapy; NBT: neutron brachytherapy." "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">Authors \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">Method \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">Number \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">Stage \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">Applicator \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">Local recurrence (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">OS (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">Late toxicity (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Inciura, et al. (16) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">HDRB +/- EBRT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">I–III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Three-channel \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">17.2 (4/29) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">48.3 (5 y) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">13.8 (4/29) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Rouanet, et al. (24) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">LDRB +/- EBRT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">147 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">I–III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">— \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">24 (36/147) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">58.4 (5 y) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">11.7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Knocke, et al. (9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">HDRB +/- EBRT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">280 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">I–III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">One-channel \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">22.9 (64/280) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">52.7 (5 y) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">23.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Churn and Jone (8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">HDRB +/- EBRT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">37 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">I-II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="top">One-channel</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="left" valign="top">16 (6/37)</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">68.4 (5 y) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="2" align="center" valign="top">—</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">III–IV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">33 (5 y) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Current study \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">NBT +/- EBRT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">31 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">I–III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">Two-channel \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">19.4 (6/31) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">51.6 (5 y) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">12.9 (4/31) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] ] "descripcion" => array:1 [ "en" => "Literature review of the outcomes of inoperable stage I-IV endometrial cancer patients receiving radiotherapy." ] ] ] "bibliografia" => array:2 [ "titulo" => "REFERENCES" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "cebibsec10" "bibliografiaReferencia" => array:24 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer statistics, 2014" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ R Siegel \n \t\t\t\t\t\t\t\t """ 1 => """ J Ma \n \t\t\t\t\t\t\t\t """ 2 => """ Z Zou \n \t\t\t\t\t\t\t\t """ 3 => """ A Jemal \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.3322/caac.21208" "Revista" => array:7 [ "tituloSerie" => "CA Cancer J Clin" "fecha" => "2014" "volumen" => "64" "numero" => "1" "paginaInicial" => "9" "paginaFinal" => "29" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24399786" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.3322/caac.21208" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.3322/caac.21208" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Report of cancer incidence and mortality in China, 2010" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ W Chen \n \t\t\t\t\t\t\t\t """ 1 => """ R Zheng \n \t\t\t\t\t\t\t\t """ 2 => """ S Zhang \n \t\t\t\t\t\t\t\t """ 3 => """ P Zhao \n \t\t\t\t\t\t\t\t """ 4 => """ H Zeng \n \t\t\t\t\t\t\t\t """ 5 => """ X Zou \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3978/j.issn.2305-5839.2014.04.05" "Revista" => array:6 [ "tituloSerie" => "Ann Transl Med" "fecha" => "2014" "volumen" => "2" "numero" => "7" "paginaInicial" => "61" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25333036" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High Dose Rate Versus Low Dose Rate Brachytherapy for Gynecological Cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => """ CG Orton \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1053/SRAO00300232" "Revista" => array:7 [ "tituloSerie" => "Semin Radiat Oncol" "fecha" => "1993" "volumen" => "3" "numero" => "4" "paginaInicial" => "232" "paginaFinal" => "239" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10717075" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1053/SRAO00300232" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/S1053-4296(05)80120-1" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biological effective dose evaluation in gynaecological brachytherapy: LDR and HDR treatments, dependence on radiobiological parameters, and treatment optimisation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => """ C Bianchi \n \t\t\t\t\t\t\t\t """ 1 => """ F Botta \n \t\t\t\t\t\t\t\t """ 2 => """ L Conte \n \t\t\t\t\t\t\t\t """ 3 => """ P Vanoli \n \t\t\t\t\t\t\t\t """ 4 => """ L Cerizza \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1007/s11547-008-0291-4" "Revista" => array:7 [ "tituloSerie" => "Radiol Med" "fecha" => "2008" "volumen" => "113" "numero" => "7" "paginaInicial" => "1068" "paginaFinal" => "1078" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18618074" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1007/s11547-008-0291-4" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1007/s11547-008-0291-4" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Californium-252 brachytherapy combined with external-beam radiotherapy for cervical cancer: long-term treatment results" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ X Lei \n \t\t\t\t\t\t\t\t """ 1 => """ CY Qian \n \t\t\t\t\t\t\t\t """ 2 => """ Y Qing \n \t\t\t\t\t\t\t\t """ 3 => """ KW Zhao \n \t\t\t\t\t\t\t\t """ 4 => """ ZZ Yang \n \t\t\t\t\t\t\t\t """ 5 => """ N Dai \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/j.ijrobp.2010.08.039" "Revista" => array:7 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "2011" "volumen" => "81" "numero" => "5" "paginaInicial" => "1264" "paginaFinal" => "1270" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21435797" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/j.ijrobp.2010.08.039" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/j.ijrobp.2010.08.039" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Californium-252 (252Cf) versus conventional gamma radiation in the brachytherapy of advanced cervical carcinoma long-term treatment results of a randomized study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => """ T Tacev \n \t\t\t\t\t\t\t\t """ 1 => """ B Ptackova \n \t\t\t\t\t\t\t\t """ 2 => """ V Strnad \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00066-003-1005-4" "Revista" => array:7 [ "tituloSerie" => "Strahlenther Onkol" "fecha" => "2003" "volumen" => "179" "numero" => "6" "paginaInicial" => "377" "paginaFinal" => "384" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12789463" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical evaluation of 252Cf neutron intracavitary therapy for primary endometrial adenocarcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => """ Y Maruyama \n \t\t\t\t\t\t\t\t """ 1 => """ NagellJR Van \n \t\t\t\t\t\t\t\t """ 2 => """ J Yoneda \n \t\t\t\t\t\t\t\t """ 3 => """ P DePriest \n \t\t\t\t\t\t\t\t """ 4 => """ RJ Kryscio \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1002/1097-0142(19930615)71:12<3932::aid-cncr2820711222>3.0.co;2-a" "Revista" => array:7 [ "tituloSerie" => "Cancer" "fecha" => "1993" "volumen" => "71" "numero" => "12" "paginaInicial" => "3932" "paginaFinal" => "3937" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8508359" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1002/1097-0142(19930615)71:12<3932::aid-cncr2820711222>3.0.co;2-a" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1002/1097-0142(19930615)71:12<3932::AID-CNCR2820711222>3.0.CO;2-A" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Primary radiotherapy for carcinoma of the endometrium using external beam radiotherapy and single line source brachytherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => """ M Churn \n \t\t\t\t\t\t\t\t """ 1 => """ B Jones \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1053/clon.1999.9059" "Revista" => array:7 [ "tituloSerie" => "Clin Oncol (R Coll Radiol)" "fecha" => "1999" "volumen" => "11" "numero" => "4" "paginaInicial" => "255" "paginaFinal" => "262" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10473723" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1053/clon.1999.9059" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1053/clon.1999.9059" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Primary treatment of endometrial carcinoma with high-dose-rate brachytherapy: results of 12 years of experience with 280 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => """ TH Knocke \n \t\t\t\t\t\t\t\t """ 1 => """ H Kucera \n \t\t\t\t\t\t\t\t """ 2 => """ B Weidinger \n \t\t\t\t\t\t\t\t """ 3 => """ W Holler \n \t\t\t\t\t\t\t\t """ 4 => """ R Potter \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/s0360-3016(96)00486-5" "Revista" => array:7 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "1997" "volumen" => "37" "numero" => "2" "paginaInicial" => "359" "paginaFinal" => "365" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9069308" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/s0360-3016(96)00486-5" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/S0360-3016(96)00486-5" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Follow-up study of clinical effects of californium-252 neutron intracavitary radiotherapy and external beam radiotherapy in endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ X Lei \n \t\t\t\t\t\t\t\t """ 1 => """ JL Shan \n \t\t\t\t\t\t\t\t """ 2 => """ C Tang \n \t\t\t\t\t\t\t\t """ 3 => """ KW Zhao \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Zhonghua Fu Chan Ke Za Zhi" "fecha" => "2007" "volumen" => "42" "numero" => "11" "paginaInicial" => "733" "paginaFinal" => "736" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18307897" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Image-guided high-dose-rate brachytherapy in inoperable endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ P Dankulchai \n \t\t\t\t\t\t\t\t """ 1 => """ J Petsuksiri \n \t\t\t\t\t\t\t\t """ 2 => """ Y Chansilpa \n \t\t\t\t\t\t\t\t """ 3 => """ PJ Hoskin \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Br J Radiol" "fecha" => "2014" "volumen" => "87" "numero" => "1039" ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1259/bjr.20140018" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Primary radiation therapy for medically inoperable patients with endometrial carcinoma–stages I-II" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ M Varia \n \t\t\t\t\t\t\t\t """ 1 => """ J Rosenman \n \t\t\t\t\t\t\t\t """ 2 => """ J Halle \n \t\t\t\t\t\t\t\t """ 3 => """ L Walton \n \t\t\t\t\t\t\t\t """ 4 => """ J Currie \n \t\t\t\t\t\t\t\t """ 5 => """ W Fowler \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/0360-3016(87)90253-7" "Revista" => array:7 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "1987 Jan" "volumen" => "13" "numero" => "1" "paginaInicial" => "11" "paginaFinal" => "15" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3804805" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/0360-3016(87)90253-7" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/0360-3016(87)90253-7" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Medically inoperable stage I adenocarcinoma of the endometrium treated with radiotherapy alone" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ PW Grigsby \n \t\t\t\t\t\t\t\t """ 1 => """ RR Kuske \n \t\t\t\t\t\t\t\t """ 2 => """ CA Perez \n \t\t\t\t\t\t\t\t """ 3 => """ BJ Walz \n \t\t\t\t\t\t\t\t """ 4 => """ MH Camel \n \t\t\t\t\t\t\t\t """ 5 => """ MS Kao \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/0360-3016(87)90061-7" "Revista" => array:7 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "1987" "volumen" => "13" "numero" => "4" "paginaInicial" => "483" "paginaFinal" => "488" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3558039" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/0360-3016(87)90061-7" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/0360-3016(87)90061-7" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ H Kucera \n \t\t\t\t\t\t\t\t """ 1 => """ TH Knocke \n \t\t\t\t\t\t\t\t """ 2 => """ E Kucera \n \t\t\t\t\t\t\t\t """ 3 => """ R Potter \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Acta Obstet Gynecol Scand" "fecha" => "1998" "volumen" => "77" "numero" => "10" "paginaInicial" => "1008" "paginaFinal" => "1012" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9849846" "web" => "Medline" ] ] ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1080/j.1600-0412.1998.771011.x" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ DA Fishman \n \t\t\t\t\t\t\t\t """ 1 => """ KB Roberts \n \t\t\t\t\t\t\t\t """ 2 => """ JT Chambers \n \t\t\t\t\t\t\t\t """ 3 => """ EI Kohorn \n \t\t\t\t\t\t\t\t """ 4 => """ PE Schwartz \n \t\t\t\t\t\t\t\t """ 5 => """ SK Chambers \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1006/gyno.1996.0123" "Revista" => array:7 [ "tituloSerie" => "Gynecol Oncol" "fecha" => "1996" "volumen" => "61" "numero" => "2" "paginaInicial" => "189" "paginaFinal" => "196" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8626131" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1006/gyno.1996.0123" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1006/gyno.1996.0123" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term results of high-dose-rate brachytherapy and external-beam radiotherapy in the primary treatment of endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ A Inciura \n \t\t\t\t\t\t\t\t """ 1 => """ V Atkocius \n \t\t\t\t\t\t\t\t """ 2 => """ E Juozaityte \n \t\t\t\t\t\t\t\t """ 3 => """ D Vaitkiene \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1269/jrr.10080" "Revista" => array:7 [ "tituloSerie" => "J Radiat Res" "fecha" => "2010" "volumen" => "51" "numero" => "6" "paginaInicial" => "675" "paginaFinal" => "681" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21116100" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1269/jrr.10080" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1269/jrr.10080" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Results of treatment in locally advanced carcinoma of the endometrium" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:9 [ 0 => """ K Ahmad \n \t\t\t\t\t\t\t\t """ 1 => """ YH Kim \n \t\t\t\t\t\t\t\t """ 2 => """ G Deppe \n \t\t\t\t\t\t\t\t """ 3 => """ J Malone \n \t\t\t\t\t\t\t\t """ 4 => """ A Herskovic \n \t\t\t\t\t\t\t\t """ 5 => """ V Ratanatharathorn \n \t\t\t\t\t\t\t\t """ 6 => """ WA Sakr \n \t\t\t\t\t\t\t\t """ 7 => """ A Medina \n \t\t\t\t\t\t\t\t """ 8 => """ V Malviya \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.3109/02841869009126546" "Revista" => array:7 [ "tituloSerie" => "Acta Oncol" "fecha" => "1990" "volumen" => "29" "numero" => "2" "paginaInicial" => "203" "paginaFinal" => "209" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2185804" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.3109/02841869009126546" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.3109/02841869009126546" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inoperable adenocarcinoma of endometrium: radiation therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => """ ML Wang \n \t\t\t\t\t\t\t\t """ 1 => """ DH Hussey \n \t\t\t\t\t\t\t\t """ 2 => """ AP Vigliotti \n \t\t\t\t\t\t\t\t """ 3 => """ J Benda \n \t\t\t\t\t\t\t\t """ 4 => """ BC Wen \n \t\t\t\t\t\t\t\t """ 5 => """ JF Doornbos \n \t\t\t\t\t\t\t\t """ 6 => """ B Anderson \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1148/radiology.165.2.3659385" "Revista" => array:7 [ "tituloSerie" => "Radiology" "fecha" => "1987" "volumen" => "165" "numero" => "2" "paginaInicial" => "561" "paginaFinal" => "565" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3659385" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1148/radiology.165.2.3659385" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1148/radiology.165.2.3659385" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Primary radiation therapy for endometrial carcinoma: a case controlled study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ PG Rose \n \t\t\t\t\t\t\t\t """ 1 => """ S Baker \n \t\t\t\t\t\t\t\t """ 2 => """ M Kern \n \t\t\t\t\t\t\t\t """ 3 => """ TJ Fitzgerald \n \t\t\t\t\t\t\t\t """ 4 => """ WK Tak \n \t\t\t\t\t\t\t\t """ 5 => """ Fr Reale \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/0360-3016(93)90383-7" "Revista" => array:7 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "1993" "volumen" => "27" "numero" => "3" "paginaInicial" => "585" "paginaFinal" => "590" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8226152" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/0360-3016(93)90383-7" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/0360-3016(93)90383-7" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dosimetric considerations in the treatment of inoperable endometrial carcinoma by a high dose rate afterloading packing technique" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ MG Bond \n \t\t\t\t\t\t\t\t """ 1 => """ G Workman \n \t\t\t\t\t\t\t\t """ 2 => """ J Martland \n \t\t\t\t\t\t\t\t """ 3 => """ JE Clinkard \n \t\t\t\t\t\t\t\t """ 4 => """ BM Carey \n \t\t\t\t\t\t\t\t """ 5 => """ RI Rothwell \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/s0936-6555(97)80060-x" "Revista" => array:7 [ "tituloSerie" => "Clin Oncol (R Coll Radiol)" "fecha" => "1997" "volumen" => "9" "numero" => "1" "paginaInicial" => "41" "paginaFinal" => "47" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9039813" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/s0936-6555(97)80060-x" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/S0936-6555(97)80060-X" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-dose-rate Rotte "Y" applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ D Coon \n \t\t\t\t\t\t\t\t """ 1 => """ S Beriwal \n \t\t\t\t\t\t\t\t """ 2 => """ DE Heron \n \t\t\t\t\t\t\t\t """ 3 => """ JL Kelley \n \t\t\t\t\t\t\t\t """ 4 => """ RP Edwards \n \t\t\t\t\t\t\t\t """ 5 => """ P Sukumvanich \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/j.ijrobp.2007.10.026" "Revista" => array:7 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "2008" "volumen" => "71" "numero" => "3" "paginaInicial" => "779" "paginaFinal" => "783" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18258388" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/j.ijrobp.2007.10.026" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/j.ijrobp.2007.10.026" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => """ TV Nguyen \n \t\t\t\t\t\t\t\t """ 1 => """ DG Petereit \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1006/gyno.1998.5148" "Revista" => array:7 [ "tituloSerie" => "Gynecol Oncol" "fecha" => "1998" "volumen" => "71" "numero" => "2" "paginaInicial" => "196" "paginaFinal" => "203" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9826460" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1006/gyno.1998.5148" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1006/gyno.1998.5148" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of 2D vs. 3D dosimetry for Rotte 'Y' applicator high dose rate brachytherapy for medically inoperable endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ S Beriwal \n \t\t\t\t\t\t\t\t """ 1 => """ H Kim \n \t\t\t\t\t\t\t\t """ 2 => """ DE Heron \n \t\t\t\t\t\t\t\t """ 3 => """ R Selvaraj \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1177/153303460600500509" "Revista" => array:7 [ "tituloSerie" => "Technol Cancer Res Treat" "fecha" => "2006" "volumen" => "5" "numero" => "5" "paginaInicial" => "521" "paginaFinal" => "527" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16981795" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1177/153303460600500509" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1177/153303460600500509" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Exclusive radiation therapy in endometrial carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ P Rouanet \n \t\t\t\t\t\t\t\t """ 1 => """ JB Dubois \n \t\t\t\t\t\t\t\t """ 2 => """ S Gely \n \t\t\t\t\t\t\t\t """ 3 => """ H Pourquier \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/0360-3016(93)90201-6" "Revista" => array:7 [ "tituloSerie" => "Int J Radiat Oncol Biol Phys" "fecha" => "1993" "volumen" => "26" "numero" => "2" "paginaInicial" => "223" "paginaFinal" => "228" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8491680" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/0360-3016(93)90201-6" "WWW" => array:1 [ "link" => "http://dx.doi.org/10.1016/0360-3016(93)90201-6" ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack638157" "titulo" => "ACKNOWLEDGMENTS" "texto" => "We first thank the patients and their families. We also thank the Departments of Obstetrics and Gynecology and of Pathology and the Imaging Center of Daping Hospital." "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/18075932/0000007100000001/v1_202211290914/S1807593222012960/v1_202211290914/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/18075932/0000007100000001/v1_202211290914/S1807593222012960/v1_202211290914/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222012960?idApp=UINPBA00004N"]

Statistics

CLINICAL SCIENCE

Qian Zhou, Cheng Tang, Ke-Wei Zhao, Yan-Li Xiong, Shu Chen, Wen-Jing Xu, Xin Lei

Corresponding author

dpxinlei@126.com

corresponding author

Third Military Medical University, Cancer Center, Research Institute of Surgery and Daping Hospital, Chongqing, China

Read

641

Times
was read the article

219

Total PDF

422

Total HTML

Share statistics

 array:24 [
  "pii" => "S1807593222012960"
  "issn" => "18075932"
  "doi" => "10.6061/clinics/2016(01)03"
  "estado" => "S300"
  "fechaPublicacion" => "2016-01-01"
  "aid" => "1296"
  "copyright" => "CLINICS"
  "copyrightAnyo" => "2016"
  "documento" => "article"
  "crossmark" => 0
  "licencia" => "https://creativecommons.org/licenses/by/4.0/"
  "subdocumento" => "fla"
  "cita" => "Clinics. 2016;71:10-6"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1807593222012972"
    "issn" => "18075932"
    "doi" => "10.6061/clinics/2016(01)04"
    "estado" => "S300"
    "fechaPublicacion" => "2016-01-01"
    "aid" => "1297"
    "copyright" => "CLINICS"
    "documento" => "article"
    "crossmark" => 0
    "licencia" => "https://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "fla"
    "cita" => "Clinics. 2016;71:17-21"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">CLINICAL SCIENCE</span>"
      "titulo" => "Severe potential drug-drug interactions in older adults with dementia and associated factors"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "17"
          "paginaFinal" => "21"
        ]
      ]
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Michele Bogetti-Salazar, Cesar Gonz&#225;lez-Gonz&#225;lez, Teresa Ju&#225;rez-Cedillo, Sergio S&#225;nchez-Garc&#237;a, Oscar Rosas-Carrasco"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Michele"
              "apellidos" => "Bogetti-Salazar"
            ]
            1 => array:2 [
              "nombre" => "Cesar"
              "apellidos" => "Gonz&#225;lez-Gonz&#225;lez"
            ]
            2 => array:2 [
              "nombre" => "Teresa"
              "apellidos" => "Ju&#225;rez-Cedillo"
            ]
            3 => array:2 [
              "nombre" => "Sergio"
              "apellidos" => "S&#225;nchez-Garc&#237;a"
            ]
            4 => array:2 [
              "nombre" => "Oscar"
              "apellidos" => "Rosas-Carrasco"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222012972?idApp=UINPBA00004N"
    "url" => "/18075932/0000007100000001/v1_202211290914/S1807593222012972/v1_202211290914/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S1807593222012959"
    "issn" => "18075932"
    "doi" => "10.6061/clinics/2016(01)02"
    "estado" => "S300"
    "fechaPublicacion" => "2016-01-01"
    "aid" => "1295"
    "copyright" => "CLINICS"
    "documento" => "article"
    "crossmark" => 0
    "licencia" => "https://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "fla"
    "cita" => "Clinics. 2016;71:5-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">CLINICAL SCIENCE</span>"
      "titulo" => "Eszopiclone <span class="elsevierStyleItalic">versus</span> zopiclone in the treatment of insomnia"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "5"
          "paginaFinal" => "9"
        ]
      ]
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Luciano Ribeiro Pinto, Lia Rita Azeredo Bittencourt, Erika Cristine Treptow, Luciano Rotella Braga, Sergio Tufik"
          "autores" => array:5 [
            0 => array:3 [
              "nombre" => "Luciano Ribeiro"
              "apellidos" => "Pinto"
              "sufijo" => "Jr"
            ]
            1 => array:2 [
              "nombre" => "Lia Rita Azeredo"
              "apellidos" => "Bittencourt"
            ]
            2 => array:2 [
              "nombre" => "Erika Cristine"
              "apellidos" => "Treptow"
            ]
            3 => array:2 [
              "nombre" => "Luciano Rotella"
              "apellidos" => "Braga"
            ]
            4 => array:2 [
              "nombre" => "Sergio"
              "apellidos" => "Tufik"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222012959?idApp=UINPBA00004N"
    "url" => "/18075932/0000007100000001/v1_202211290914/S1807593222012959/v1_202211290914/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">CLINICAL SCIENCE</span>"
    "titulo" => "Clinical assessment of <span class="elsevierStyleSup">252</span>Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "10"
        "paginaFinal" => "16"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Qian Zhou,  Cheng Tang, Ke-Wei Zhao, Yan-Li Xiong, Shu Chen, Wen-Jing Xu, Xin Lei"
        "autores" => array:7 [
          0 => array:2 [
            "nombre" => "Qian"
            "apellidos" => "Zhou"
          ]
          1 => array:1 [
            "apellidos" => "Cheng Tang"
          ]
          2 => array:2 [
            "nombre" => "Ke-Wei"
            "apellidos" => "Zhao"
          ]
          3 => array:2 [
            "nombre" => "Yan-Li"
            "apellidos" => "Xiong"
          ]
          4 => array:2 [
            "nombre" => "Shu"
            "apellidos" => "Chen"
          ]
          5 => array:2 [
            "nombre" => "Wen-Jing"
            "apellidos" => "Xu"
          ]
          6 => array:4 [
            "nombre" => "Xin"
            "apellidos" => "Lei"
            "email" => array:1 [
              0 => "dpxinlei@126.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "&#42;"
                "identificador" => "cor1"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Third Military Medical University&#44; Cancer Center&#44; Research Institute of Surgery and Daping Hospital&#44; Chongqing&#44; China"
            "identificador" => "aff1"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor1"
            "etiqueta" => "&#42;"
            "correspondencia" => "corresponding author"
          ]
        ]
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig2"
        "etiqueta" => "Figure 2-"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 599
            "Ancho" => 648
            "Tamanyo" => 50571
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara20" class="elsevierStyleSimplePara elsevierViewall">Isodose contour showing that the dose at point F was nearly identical to that at point A in stage II and III patients&#46; A and F denote dose reference points A and F&#44; respectively&#46; The cervix is indicated by arrows and the uterus is indicated by curled arrows&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="cesec10" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle60">INTRODUCTION</span><p id="para10" class="elsevierStylePara elsevierViewall">Endometrial cancer is one of the most common gynecologic malignancies worldwide&#46; According to a report from the American Cancer Society&#44; approximately 52&#44;630 new cases of endometrial cancer were diagnosed and 8&#44;590 deaths were associated with endometrial cancer in the United States in 2014 <a class="elsevierStyleCrossRef" href="#bib1">1</a>&#46; The National Cancer Institute of China estimated that there would be 47&#44;751 new cases of endometrial cancer in China in 2010 <a class="elsevierStyleCrossRef" href="#bib2">2</a>&#46; Currently&#44; surgery remains the standard treatment for early-stage endometrial cancer&#46; However&#44; radiation has become a more suitable treatment option for patients with medically inoperable endometrial cancer or for those of advanced age&#46;</p><p id="para20" class="elsevierStylePara elsevierViewall">In terms of a definitive radiotherapy for endometrial cancer&#44; intracavitary brachytherapy &#40;ICBT&#41; alone can be used to treat stage I patients&#46; Moreover&#44; ICBT combined with external beam radiotherapy &#40;EBRT&#41; can be used to treat patients with local advanced-stage endometrial cancer&#46; Generally&#44; there are two types of brachytherapy using conventional &#947;-rays&#58; high-dose-rate &#40;HDR&#41; brachytherapy using <span class="elsevierStyleSup">192</span>Ir or low-dose-rate &#40;LDR&#41; brachytherapy using <span class="elsevierStyleSup">137</span>Cs&#46; There have been no randomized controlled trials &#40;RCT&#41; comparing the effects of HDR brachytherapy and LDR brachytherapy on endometrial cancer in recent years because endometrial cancer is rarely treated with radiotherapy alone <a class="elsevierStyleCrossRef" href="#bib3">3</a>&#44;<a class="elsevierStyleCrossRef" href="#bib4">4</a>&#46;</p><p id="para30" class="elsevierStylePara elsevierViewall">Many reports in the literature have described the use of californium-252 &#40;<span class="elsevierStyleSup">252</span>Cf&#41; as a neutron source for the treatment of cervical cancer due to its higher relative biologic effectiveness &#40;RBE&#41; and lower oxygen enhancement rate &#40;OER&#41; than &#947;-rays <a class="elsevierStyleCrossRef" href="#bib5">5</a>&#44;<a class="elsevierStyleCrossRef" href="#bib6">6</a>&#46; Moreover&#44; the <span class="elsevierStyleSup">252</span>Cf neutron source has been used effectively for ICBT of endometrial cancer <a class="elsevierStyleCrossRef" href="#bib7">7</a>&#46; However&#44; a single-channel applicator was used in most endometrial cancer studies <a class="elsevierStyleCrossRef" href="#bib8">8</a>&#44;<a class="elsevierStyleCrossRef" href="#bib9">9</a>&#44; including our own&#44; which is described below <a class="elsevierStyleCrossRef" href="#bib10">10</a>&#46; The use of a single-channel applicator has several drawbacks&#44; including longer treatment durations and a slightly higher incidence of complications than the use of a two-channel applicator <a class="elsevierStyleCrossRef" href="#bib9">9</a>&#46; Further&#44; the dose distribution associated with a single-channel applicator is not ideal and is difficult to adjust&#46; Between 1999 and 2004&#44; our center performed <span class="elsevierStyleSup">252</span>Cf neutron ICBT using a single-channel applicator to treat 40 cases of endometrial cancer and we observed the above-described shortcomings associated with this method &#40;i&#46;e&#46;&#44; long treatment durations&#44; a high rate of complications and difficulty in adjusting the dose and the dose distribution&#41;&#46;</p><p id="para40" class="elsevierStylePara elsevierViewall">The modification of two-channel &#40;TC&#41; Y &#40;Rotte Y&#41; applicators for brachytherapy has overcome many of the shortcomings associated with single-channel applicators&#44; particularly with regard to adjustment of the optimal dose distribution in the craniocaudal and lateral directions&#46; Therefore&#44; TC applicators have become the standard fixed applicators used for &#947;-ray ICBT of endometrial cancer <a class="elsevierStyleCrossRef" href="#bib11">11</a>&#46;</p><p id="para50" class="elsevierStylePara elsevierViewall">In 2007&#44; our center began employing a <span class="elsevierStyleSup">252</span>Cf neutron source using the TC applicator for endometrial cancer treatment&#46; The aim of this study was to assess the clinical outcomes of endometrial cancer patients treated via <span class="elsevierStyleSup">252</span>Cf neutron ICBT using a TC applicator combined with EBRT&#46;</p></span><span id="cesec20" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle70">MATERIALS AND METHODS</span><span id="cesec30" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle80">Subjects</span><p id="para60" class="elsevierStylePara elsevierViewall">Thirty-one stage I&#8211;III endometrial cancer patients diagnosed based on biopsy findings and staged according to the International Federation of Gynecology and Obstetrics &#40;FIGO&#41; guidelines from September 2007 to August 2011 were included in this study&#46; Among these patients&#44; the most common comorbidities associated with receiving radiotherapy alone included hypertension and diabetes &#40;<a class="elsevierStyleCrossRef" href="#tbl1">Table 1</a>&#41;&#46; None of the patients had received treatment before the study&#44; and all endometrial cancer diagnoses had been confirmed by histology&#46; All of the patients exhibited Karnofsky scores greater than 70 and hemoglobin levels greater than 90 g&#47;L&#59; their mean age was 55&#46;9 years &#40;range&#58; 30&#8211;72 years&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl1">Table 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl1"></elsevierMultimedia><p id="para70" class="elsevierStylePara elsevierViewall">All of the patients underwent a chest x-ray&#44; an abdominal B-ultrasound&#44; a pelvic CT or MRI&#44; cystoscopy and a colonoscopy as components of their pre-treatment evaluation&#46; During the course of treatment&#44; a pelvic B-ultrasound and a gynecological examination were performed every week to examine changes in uterine size and uterine cavity depth&#46;</p></span><span id="cesec40" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle90">Treatment methods</span><span id="cesec50" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle100">Equipment</span><p id="para80" class="elsevierStylePara elsevierViewall">An LZH-1000 <span class="elsevierStyleSup">252</span>Cf neutron brachytherapy machine &#40;Shenzhen Lingdun Technology&#44; Shenzhen&#44; China&#41; and an 8 MV&#47;X linear accelerator &#40;Elekta Corp&#46;&#44; Stockholm&#44; Sweden&#41; were used&#46; For the 252Cf neutron source&#44; the average energy was 2&#46;3 MeV&#44; with a half-life of 2&#46;645 years&#59; the shape was cylindrical with dimensions of 3 mm in diameter &#215; 8 mm in height&#44; an active region of 1&#46;4 mm &#215; 9&#46;0 mm&#44; and a source strength per unit volume of 500&#8211;200 &#956;g&#46; The following formula was used to calculate the 252Cf dose&#58; equivalent biological dose &#40;<span class="elsevierStyleItalic">DGY-eq</span>&#41; &#61; neutron relative biological effectiveness &#40;RBE&#41; of 252Cf &#215; <span class="elsevierStyleSup">252</span>Cf neutron dose &#43; &#947;-ray RBE x &#947;-ray dose&#59; the 252Cf RBE ranged from between 4&#8211;6&#46;</p></span><span id="cesec60" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle110">Treatment plan</span><p id="para90" class="elsevierStylePara elsevierViewall">Stage I patients underwent <span class="elsevierStyleSup">252</span>Cf neutron ICBT using the TC applicator alone&#46; Stage II or III patients underwent <span class="elsevierStyleInf">252</span>Cf neutron ICBT using the TC applicator combined with EBRT&#46; All patients were hospitalized throughout the treatment period&#46; External radiation was applied four times per week with opposing fields and a dose per fraction of 2 Gy&#46; Once the total dose reached 20&#8211;36 Gy in 10&#8211;18 fractions&#44; the central portion of the field was shielded using a 4 cm thick lead block&#44; and the treatment was continued with antero-posterior field irradiation until the total dose reached 46&#8211;50 Gy&#46; 252Cf neutron ICBT using the TC applicator was delivered after 4&#8211;5 fractions of EBRT&#46; ICBT then continued once per week&#44; with the EBRT applied on 4 other days of the week&#46; The total treatment duration was 6-7 weeks&#46; A non-steroidal painkiller or morphine was administered before applicator placement&#46; Barium enemas and bladder catheterizations were prepared prior to injection of the contrast agent into the balloon&#46; Then&#44; between 7 and 12 cervical dilatation rods were used sequentially to gradually expand the cervix until it was sufficiently enlarged&#46; The two channels of the applicator were turned to a vertical position such that the two front ends were closed together&#44; followed by insertion of the fundus was inserted into the uterus&#46; The TC applicator was then turned to the horizontal position such that the top of the two channels reached the two horns of the uterus&#44; and an anterolateral image was captured &#40;<a class="elsevierStyleCrossRef" href="#fig1">Figure 1</a>&#41;&#46; Points A and F &#40;point F was defined on line A&#44; 2 cm lateral to the top of the TC applicator&#41; were chosen as the dose reference points&#46; The brachytherapy dose was 40&#8211;45 Gy to point A and 48&#8211;55 Gy to point F in 4&#8211;5 fractions&#46; For stage I patients&#44; the dose at point F was higher than that at point A&#46; For stage II or III patients&#44; the dose at point F was approximately the same as that at point A &#40;<a class="elsevierStyleCrossRef" href="#fig2">Figure 2</a>&#41;&#46; The dose at the posterior wall of the bladder and the rectum was adjusted based on the isodose contour so that the dose at the bladder and the rectum was below 80&#37; of that at point A&#46; Stage I or II patients were administered a single channel and a vault tube of internal irradiation &#40;<a class="elsevierStyleCrossRef" href="#fig3">Figure 3</a>&#41; to supplement potentially insufficient doses at the uterine fundus and the vaginal fornix&#46; The ratio of the dose applied to the cervix to the dose applied to the vaginal fornix was 1&#46;0&#58;&#40;0&#46;8&#8211;1&#46;0&#41; for stage I patients &#40;<a class="elsevierStyleCrossRef" href="#fig4">Figure 4</a>&#41; and 1&#46;0&#58;&#40;1&#46;2&#8211;1&#46;4&#41; for stage II patients &#40;<a class="elsevierStyleCrossRef" href="#fig5">Figure 5</a>&#41;&#46; During 252Cf neutron ICBT using the TC applicator&#44; the patients were monitored for symptom alleviation&#44; and gynecological examinations were performed weekly to determine the size of the uterus and the extent of tumor regression&#46; At six months post-treatment&#44; uterine curettage and histopathological examination were performed to examine tumor cell regression&#46;</p><elsevierMultimedia ident="fig1"></elsevierMultimedia><elsevierMultimedia ident="fig2"></elsevierMultimedia><elsevierMultimedia ident="fig3"></elsevierMultimedia><elsevierMultimedia ident="fig4"></elsevierMultimedia><elsevierMultimedia ident="fig5"></elsevierMultimedia></span><span id="cesec70" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle120">Follow-ups</span><p id="para100" class="elsevierStylePara elsevierViewall">Beginning one month post-treatment&#44; a pelvic B-ultrasound was performed monthly&#46; At three months post-treatment&#44; uterine curettage and histopathological examination of the endometrial tissues were performed&#46; Outpatient follow-up visits were required once every three months beginning three months post-treatment and once every six months beginning one year post-treatment&#46; None of the patients were lost to follow-up&#46;</p></span><span id="cesec80" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle130">Statistical analysis</span><p id="para110" class="elsevierStylePara elsevierViewall">SPSS13&#46;0 software was used for statistical analyses&#46; Discrete data are presented as frequencies &#40;percentages&#41;&#59; continuous data are presented as means &#177; SE&#46; For statistical analyses&#44; Chi-square contingency table analysis and Kaplan-Meier tests were performed&#59; <span class="elsevierStyleItalic">p-</span>values&#60;0&#46;05 were considered statistically significant &#40;<a class="elsevierStyleCrossRefs" href="#tbl2">Tables 2 and 3</a>&#41;&#46;</p><elsevierMultimedia ident="tbl2"></elsevierMultimedia><elsevierMultimedia ident="tbl3"></elsevierMultimedia></span><span id="cesec90" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle140">Ethics</span><p id="para120" class="elsevierStylePara elsevierViewall">This study was approved by the ethics committee of our hospital&#44; and all patients signed informed consent forms&#46;</p></span></span></span><span id="cesec100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle150">RESULTS</span><p id="para130" class="elsevierStylePara elsevierViewall">The mean follow-up duration was 54&#46;8 months&#46; Of the 31 patients enrolled in this study&#44; 15 patients died during the follow-up period&#46; One of the stage I patients died as a result of fatal coronary artery disease&#46; Two stage III patients died from the persistent tumor&#46; Three deceased patients had pelvic lymph node recurrence&#44; four deceased patients had local recurrence at the time of death&#44; and five deceased patients had distant metastases&#46; The mean overall survival duration was 61&#46;8&#177;5&#46;2 months&#44; with a 95&#37; confidence interval of 51&#46;6&#8211;72&#46;0 months &#40;<a class="elsevierStyleCrossRef" href="#tbl3">Table 3</a>&#41;&#46; The 5-year overall survival rate for all patients was 51&#46;6&#37; &#40;<a class="elsevierStyleCrossRef" href="#fig6">Figure 6</a>&#41;&#46; The disease-specific survival &#40;DSS&#41; rates for stages I&#44; II&#44; and III were 100&#37;&#44; 54&#46;5&#37;&#44; and 0&#37;&#44; respectively &#40;<a class="elsevierStyleCrossRef" href="#tbl2">Table 2</a>&#41;&#46;</p><elsevierMultimedia ident="fig6"></elsevierMultimedia><p id="para140" class="elsevierStylePara elsevierViewall">Following treatment via <span class="elsevierStyleSup">252</span>Cf neutron ICBT using the TC applicator combined with EBRT&#44; both pelvic B-ultrasound and gynecological examination showed that the uterus had shrunk substantially in all 31 patients and that the uterine cavity depth was reduced to a varying extent &#40;0&#46;5&#8211;5&#46;0 cm&#41;&#46; Of the two locally uncontrolled patients treated with an additional fraction of <span class="elsevierStyleSup">252</span>Cf neutron ICBT using the TC applicator&#44; one experienced locally controlled disease&#44; and the other&#44; who showed clear cell histology&#44; experienced local failure&#46; The most common locations of disease recurrence were distant &#40;16&#46;1&#37;&#41;&#44; local recurrence alone &#40;12&#46;9&#37;&#41;&#44; and pelvic lymph nodes &#40;9&#46;6&#37;&#41;&#46; Of the five patients with distant tumor recurrence&#44; three exhibited a single distant tumor involving the lungs and bone&#44; and two exhibited multi-organ involvement&#46; Additionally&#44; patients with comorbid endometrial cancer and diabetes were more susceptible to metastasis development and disease recurrence &#40;8&#47;31&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl4">Table 4</a>&#41;&#46;</p><elsevierMultimedia ident="tbl4"></elsevierMultimedia><p id="para150" class="elsevierStylePara elsevierViewall">All patients completed the treatment without interruption&#46; All of the late complications were limited to grade 2&#44; and there were no recto-vaginal or vesico-vaginal fistulas&#46; Three patients had frequent urination&#44; urgency&#44; and hematuria at 26 months post-radiotherapy&#46; Cystoscopic examination ruled out other diseases&#44; and these patients were diagnosed with radiation cystitis&#46; Another patient was diagnosed with radiation proctitis&#46; The incidence of late complications was 12&#46;9&#37; &#40;4&#47;31&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl5">Table 5</a>&#41;&#46;</p><elsevierMultimedia ident="tbl5"></elsevierMultimedia></span><span id="cesec110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle160">DISCUSSION</span><p id="para160" class="elsevierStylePara elsevierViewall">Surgery remains the primary standard treatment for patients with endometrial cancer&#46; Definitive radiotherapy is typically offered to patients who suffer from medical comorbidities and those who have locally advanced tumors&#44; as surgery may be not suitable for these patients&#46; Therefore&#44; patients treated via radiotherapy have a higher mortality rate than those treated via surgery&#46; Nevertheless&#44; radiotherapy remains the best option for patients with inoperable endometrial cancer&#46; Thus&#44; comparisons of survival between surgery and radiotherapy alone are of limited value&#46; Patients with inoperable endometrial cancer are generally treated via ICBT alone or in combination with EBRT&#46;</p><p id="para170" class="elsevierStylePara elsevierViewall">The most common histological type of endometrial cancer is adenocarcinoma&#44; which is not as sensitive to conventional radiation as squamous cell carcinoma&#46; Moreover&#44; locally advanced stage endometrial tumors are often bulky and contain many hypoxic cells&#44; which are resistant to conventional radiation&#46; In contrast to conventional radioisotopes&#44; the <span class="elsevierStyleSup">252</span>Cf neutron represents a high linear energy transfer &#40;LET&#41; ray with distinct radiation and biological characteristics&#46; For example&#44; the <span class="elsevierStyleSup">252</span>Cf neutron can cause greater direct damage to tumor cell DNA&#44; leading to a higher rate of DNA double-strand breaks&#44; than conventional photon radiation&#46; The <span class="elsevierStyleSup">252</span>Cf neutron also has a higher RBE and a lower OER than photons <a class="elsevierStyleCrossRef" href="#bib7">7</a>&#46; Thus&#44; bulky endometrial adenocarcinoma cells may be particularly sensitive to <span class="elsevierStyleSup">252</span>Cf neutrons&#44; and this form of radiotherapy could be used to treat endometrial adenocarcinoma patients&#46;</p><p id="para180" class="elsevierStylePara elsevierViewall">However&#44; <span class="elsevierStyleSup">252</span>Cf neutron ICBT has not been the main method of choice for endometrial cancer because the neutron source used for ICBT is large and expensive and because it is difficult to achieve precise biological equivalent dose calibration using conventional &#947;-rays&#46; Thus&#44; <span class="elsevierStyleSup">192</span>Ir and <span class="elsevierStyleSup">137</span>Cs ICBT are the most commonly used forms of ICBT worldwide&#44; especially in Western Europe and North America&#46; Moreover&#44; the <span class="elsevierStyleSup">252</span>Cf neutron source used for ICBT was a neutron TC applicator that was larger than the &#947;-ray TC applicator&#46; Dilatation of the cervix and the uterus is required to insert the TC applicator&#46; In general&#44; all of the endometrial cancer patients in our study tolerated TC applicator implantation well&#46; Patients with late toxicity to radiotherapy in our study had grade 2 complications and were diagnosed with radiation proctitis or radiation cystitis&#46;</p><p id="para190" class="elsevierStylePara elsevierViewall">Patients with locally advanced stage endometrial adenocarcinoma or with inoperable endometrial adenocarcinoma who are treated via a combination of &#947;-ray ICBT and EBRT often suffer from local-regional relapse&#46; In the past two decades&#44; the local control rate for patients with locally advanced stage endometrial adenocarcinoma has remained unsatisfactory&#44; even when a salvage radical hysterectomy was performed&#46; The local control rate was 76&#8211;84&#37; for stage I&#8211;III endometrial adenocarcinoma patients treated via a combination of &#947;-ray ICBT and EBRT&#46; Alternatively&#44; <span class="elsevierStyleSup">252</span>Cf neutron ICBT has been found to be effective as a radiotherapy and to have radiobiological advantages for the treatment of radio-resistant advanced or bulky endometrial tumors <a class="elsevierStyleCrossRef" href="#bib7">7</a>&#46; Our data showed that the local control rate for stage I&#8211;III endometrial adenocarcinoma patients was 80&#46;6&#37;&#46; However&#44; the local relapse rate of patients with stage I&#8211;II disease was 14&#46;8&#37; &#40;4&#47;27&#41;&#44; and that of patients with stage III disease was 50&#37;&#46;</p><p id="para200" class="elsevierStylePara elsevierViewall">The selection of an applicator is also important for ICBT of endometrial adenocarcinoma&#46; The TC &#8220;Y&#8221; applicator consists of two rigid applicators&#44; which can reach the two uterine horns&#44; permitting coverage of a greater uterine width than a single-channel applicator&#46; The dose distribution of the TC applicator was more optimal than that of the single-channel applicator&#44; such that a satisfactory local control rate might be more effectively achieved using the TC for ICBT of endometrial adenocarcinoma&#46; However&#44; few studies have examined the application of the &#8220;Y&#8221; applicator for treating endometrial cancer&#46; Ohkubo et al&#46; reported a satisfactory local control rate in ten patients with stage I&#8211;II endometrial cancer&#44; none of whom suffered from local recurrence at five years <a class="elsevierStyleCrossRef" href="#bib12">12</a>&#46; The same TC applicator was used by Coon et al&#46; to treat 49 endometrial cancer patients &#40;most of whom had stage I disease&#41; via HDR ICBT&#59; in that study&#44; three patients &#40;6&#46;1&#37;&#41; experienced local failure and the median time to disease recurrence was 17 months&#46; These two studies showing low rates of local recurrence further show that the radiation doses were sufficient for destroying the tumor in the uterus&#46;</p><p id="para210" class="elsevierStylePara elsevierViewall">Differences in tumor stages and differential tumor grades are associated with distinct outcomes of endometrial cancer patients&#46; Without question&#44; higher tumor stage&#44; lower differential tumor grade&#44; and unfavorable tumor histological type are associated with poorer prognosis&#46; Previous studies had shown that the five-year overall survival rates of stage I&#8211;III endometrial cancer patients treated via either <span class="elsevierStyleSup">137</span>Cs or <span class="elsevierStyleSup">192</span>Ir ICBT&#44; with or without EBRT <span class="elsevierStyleSup">1-5</span><a class="elsevierStyleCrossRef" href="#bib9">9</a>&#44;&#46; In contrast&#44; in the study by Maruyama et al&#46;&#44; <span class="elsevierStyleSup">252</span>Cf neutron ICBT combined with EBRT and hysterectomy resulted in five-year overall survival rates of 83&#37; for stage I&#44; 37&#37; for stage II&#44; and 50&#37; for stage III endometrial cancer patients <a class="elsevierStyleCrossRef" href="#bib7">7</a>&#46; Our current data showed a five-year overall survival rate of 51&#46;6&#37;&#59; this result is consistent with other results of LDR and HDR studies&#44; although it is lower than that from the study by Maruyama et al&#46; We speculate that the primary reason for the higher survival rate in the study by Maruyama et al&#46; was that nearly half of the patients &#40;14&#47;31&#41; in that study underwent a hysterectomy after receiving radiation therapy&#59; the survival rate of 50&#37; for stage III patients in that study was much higher than that in a previous report&#44; which showed a survival rate of only 17&#46;5&#37; among those undergoing radiotherapy alone <a class="elsevierStyleCrossRef" href="#bib17">17</a>&#46;</p><p id="para220" class="elsevierStylePara elsevierViewall">Treatment via <span class="elsevierStyleSup">252</span>Cf neutron ICBT combined with EBRT as performed in our study may be sufficient for patients with stage I&#8211;II endometrial cancer&#44; as these patients showed a five-year overall survival rate of 59&#46;3&#37;&#46; This survival rate is comparable to previous reports showing overall survival rates of 42&#8211;61&#37; for stage I&#8211;II endometrial cancer patients <a class="elsevierStyleCrossRefs" href="#bib18">18&#8211;21</a>&#46; Our treatment outcomes for the four patients with stage III endometrial cancer showed an unsatisfactory mean survival duration of 15&#46;3&#177;6&#46;0 months&#46; Two stage III patients died with persistent tumors&#46; Regarding the other two stage III patients&#44; one died 20 months post-treatment due to lung metastasis&#44; and the other exhibited pelvic lymph node recurrence at 30 months of follow-up&#46; These findings suggest that alternative treatment strategies should be used for patients with stage III endometrial cancer&#46;</p><p id="para230" class="elsevierStylePara elsevierViewall">In the course of using the &#8220;Y&#8221; applicator to treat endometrial cancer&#44; two ovoids or a ring applicator and a single-channel applicator should be added to supplement the radiation dose to the vaginal vault&#59; such a treatment generally increases the radiation dose to the bladder and the rectum&#46; In fact&#44; we observed late toxicity of grade 2 in 12&#46;9&#37; &#40;4&#47;31&#41; of the patients&#59; this frequency is similar to the results from most studies of stage I&#8211;III patients &#40;<a class="elsevierStyleCrossRef" href="#tbl6">Table 6</a>&#41;&#46; However&#44; a study of 36 stage I patients by Nguyen et al&#46; using one tandem and one ovoid or cylindrical applicator to perform HDR ICBT alone showed a frequency of late toxicity of up to 21&#37; <span class="elsevierStyleSup">6</span><a class="elsevierStyleCrossRef" href="#bib22">22</a>&#46;</p><elsevierMultimedia ident="tbl6"></elsevierMultimedia><p id="para240" class="elsevierStylePara elsevierViewall">Although much effort has been invested to identify more effective methods for ICBT of endometrial cancer&#44; no completely satisfactory method has been established&#46; Our retrospective study contains several limitations&#44; including the accuracy of cancer diagnosis and staging&#44; the socioeconomic status of the patients&#44; advances in treatment&#44; and nurse-led supportive care&#46; In particular&#44; we used 2-D treatment planning&#44; which is not as effective as 3-D planning for reducing the dose to at-risk organs <a class="elsevierStyleCrossRef" href="#bib23">23</a>&#46;</p><p id="para250" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleSup">252</span>Cf neutron ICBT using a TC applicator combined with EBRT is effective for the treatment of endometrial cancer&#44; and the incidence of serious late complications related to this therapy is acceptable&#46;</p></span><span id="cesec120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle170">AUTHORS CONTRIBUTION</span><p id="para260" class="elsevierStylePara elsevierViewall">Zhou Q participated in patients care&#44; wrote the first draft of the manuscript and performed the literature review&#46; Tang C&#44; Lei X were responsible for the patient care&#44; study design&#44; draft of the manuscript and intellectual inputs&#46; Zhao KW&#44; Jia L&#44; Shan JL&#44; Xiong YL&#44; Chen S&#44; Xu Wen-Jing were responsible for data collection&#44; data analysis and manuscript writing&#46; All authors read and approved the final version of the manuscript&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:8 [
        0 => array:2 [
          "identificador" => "xpalclavsec1580181"
          "titulo" => "KEYWORDS"
        ]
        1 => array:2 [
          "identificador" => "cesec10"
          "titulo" => "INTRODUCTION"
        ]
        2 => array:3 [
          "identificador" => "cesec20"
          "titulo" => "MATERIALS AND METHODS"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "cesec30"
              "titulo" => "Subjects"
            ]
            1 => array:3 [
              "identificador" => "cesec40"
              "titulo" => "Treatment methods"
              "secciones" => array:5 [
                0 => array:2 [
                  "identificador" => "cesec50"
                  "titulo" => "Equipment"
                ]
                1 => array:2 [
                  "identificador" => "cesec60"
                  "titulo" => "Treatment plan"
                ]
                2 => array:2 [
                  "identificador" => "cesec70"
                  "titulo" => "Follow-ups"
                ]
                3 => array:2 [
                  "identificador" => "cesec80"
                  "titulo" => "Statistical analysis"
                ]
                4 => array:2 [
                  "identificador" => "cesec90"
                  "titulo" => "Ethics"
                ]
              ]
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "cesec100"
          "titulo" => "RESULTS"
        ]
        4 => array:2 [
          "identificador" => "cesec110"
          "titulo" => "DISCUSSION"
        ]
        5 => array:2 [
          "identificador" => "cesec120"
          "titulo" => "AUTHORS CONTRIBUTION"
        ]
        6 => array:2 [
          "identificador" => "xack638157"
          "titulo" => "ACKNOWLEDGMENTS"
        ]
        7 => array:1 [
          "titulo" => "REFERENCES"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2015-07-07"
    "fechaAceptado" => "2015-11-09"
    "PalabrasClave" => array:1 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "KEYWORDS"
          "identificador" => "xpalclavsec1580181"
          "palabras" => array:3 [
            0 => "Endometrial Cancer"
            1 => "Californium"
            2 => "Two-Channel Y Applicator"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:1 [
      "en" => array:2 [
        "resumen" => "<span id="ceabs10" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle10">OBJECTIVE&#58;</span><p id="spara130" class="elsevierStyleSimplePara elsevierViewall">The aim of this study was to determine the efficacy of <span class="elsevierStyleSup">252</span>Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for the treatment of endometrial cancer&#46;</p></span> <span id="ceabs20" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle20">METHODS&#58;</span><p id="spara140" class="elsevierStyleSimplePara elsevierViewall">Thirty-one patients with stage I&#8211;III endometrial cancer were recruited for this study&#46; The stage I patients received only <span class="elsevierStyleSup">252</span>Californium neutron intracavitary brachytherapy with a two-channel applicator&#46; The stage II and III patients received both <span class="elsevierStyleSup">252</span>Californium neutron intracavitary brachytherapy using a two-channel applicator and parallel-opposed whole pelvic radiotherapy&#46;</p></span> <span id="ceabs30" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle30">RESULTS&#58;</span><p id="spara150" class="elsevierStyleSimplePara elsevierViewall">The five-year local control rate was 80&#46;6&#37; &#40;25&#47;31&#41;&#44; the overall survival rate was 51&#46;6&#37; &#40;16&#47;31&#41;&#44; and the disease-free survival rate was 54&#46;8&#37; &#40;17&#47;31&#41;&#46; The incidence of serious late complications was 12&#46;9&#37; &#40;4&#47;31&#41;&#46;</p></span> <span id="ceabs40" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle40">CONCLUSIONS&#58;</span><p id="spara160" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">252</span>Californium neutron intracavitary brachytherapy using a two-channel applicator combined with external beam radiotherapy was effective for treating endometrial cancer and the incidence of serious late complications related to this combination was within an acceptable range&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "ceabs10"
            "titulo" => "OBJECTIVE&#58;"
          ]
          1 => array:2 [
            "identificador" => "ceabs20"
            "titulo" => "METHODS&#58;"
          ]
          2 => array:2 [
            "identificador" => "ceabs30"
            "titulo" => "RESULTS&#58;"
          ]
          3 => array:2 [
            "identificador" => "ceabs40"
            "titulo" => "CONCLUSIONS&#58;"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:1 [
        "nota" => "<p class="elsevierStyleNotepara" id="cenpara30">No potential conflict of interest was reported&#46;</p>"
      ]
    ]
    "multimedia" => array:12 [
      0 => array:7 [
        "identificador" => "fig1"
        "etiqueta" => "Figure 1-"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 446
            "Ancho" => 800
            "Tamanyo" => 36147
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara10" class="elsevierStyleSimplePara elsevierViewall">A&#41; Antero-posterior view&#59; B&#41; anterolateral view&#46; The anterolateral image was captured when the TC applicator was turned to the horizontal position&#59; this image shows that the top of the two channels reached the two horns of the uterus&#46; A and F denote dose reference points A and F&#44; respectively&#46; The cervix is indicated by arrows&#44; and the uterus is indicated by curled arrows&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig2"
        "etiqueta" => "Figure 2-"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 599
            "Ancho" => 648
            "Tamanyo" => 50571
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara20" class="elsevierStyleSimplePara elsevierViewall">Isodose contour showing that the dose at point F was nearly identical to that at point A in stage II and III patients&#46; A and F denote dose reference points A and F&#44; respectively&#46; The cervix is indicated by arrows and the uterus is indicated by curled arrows&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig3"
        "etiqueta" => "Figure 3-"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 877
            "Ancho" => 780
            "Tamanyo" => 29811
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara30" class="elsevierStyleSimplePara elsevierViewall">Image showing the method by which stage I and II endometrial cancer patients were administered a single channel and a vault tube of internal irradiation to supplement potentially insufficient doses at the uterine fundus and the vaginal fornix&#46; A and F denote dose reference points A and F&#44; respectively&#46; The cervix is indicated by arrows&#44; and the uterus is indicated by curled arrows&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "fig4"
        "etiqueta" => "Figure 4-"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 635
            "Ancho" => 650
            "Tamanyo" => 62138
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara40" class="elsevierStyleSimplePara elsevierViewall">Isodose contour showing that the ratio of the dose applied to the cervix to the dose applied to the vaginal fornix was 1&#46;0&#58;&#40;0&#46;8&#8211;1&#46;0&#41; in stage I patients&#46; A and F denote dose reference points A and F&#44; respectively&#46; The cervix is indicated by arrows&#44; and the uterus is indicated by curled arrows&#46;</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "fig5"
        "etiqueta" => "Figure 5-"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr5.jpeg"
            "Alto" => 624
            "Ancho" => 648
            "Tamanyo" => 52981
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara50" class="elsevierStyleSimplePara elsevierViewall">Isodose contour showing that the ratio of the dose applied to the cervix to the dose applied to the vaginal fornix was 1&#46;0&#58;&#40;1&#46;2&#8211;1&#46;4&#41; in stage II patients&#46; A and F denote dose reference points A and F&#44; respectively&#46; The cervix is indicated by arrows&#44; and the uterus is indicated by curled arrows&#46;</p>"
        ]
      ]
      5 => array:7 [
        "identificador" => "fig6"
        "etiqueta" => "Figure 6-"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr6.jpeg"
            "Alto" => 522
            "Ancho" => 650
            "Tamanyo" => 23917
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara60" class="elsevierStyleSimplePara elsevierViewall">Survival curves of patients with different stages of endometrial cancer&#46;</p>"
        ]
      ]
      6 => array:7 [
        "identificador" => "tbl1"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Characteristics&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Number of patients &#40;&#37;&#41;<a class="elsevierStyleCrossRef" href="#tfn1">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">Total number of patients</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="top">31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">Age &#40;y&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>30&#8211;50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">5 &#40;16&#46;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>51&#8211;60&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">18 &#40;58&#46;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>61&#8211;72&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">8 &#40;26&#46;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Mean&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="top">55&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">BMI &#40;kg&#47;m<span class="elsevierStyleSup">2</span>&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Mean&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="top">27&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Range&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="top">20&#8211;41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">Stage &#40;FIGO&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>I&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">5 &#40;16&#46;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">22 &#40;71&#46;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">4 &#40;13&#46;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">Morphology</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Adenocarcinoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">28 &#40;90&#46;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Clear cell carcinoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">3 &#40;10&#46;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">Histopathologic grade</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">11 &#40;35&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">13 &#40;41&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">5 &#40;16&#46;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Unknown&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">2 &#40;6&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">Comorbid diseases</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Hypertension&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">11 &#40;35&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Diabetes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">11 &#40;35&#46;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Coronary artery disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">3 &#40;9&#46;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Systemic lupus erythematosus&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">2 &#40;6&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Others<a class="elsevierStyleCrossRef" href="#tfn2">&#42;&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">4 &#40;12&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tfn1"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="cenpara10">Thirty-one patients were enrolled in the study&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tfn2"
              "etiqueta" => "&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="cenpara20">Others included refusal of surgery or severe chronic obstructive pulmonary disease&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara70" class="elsevierStyleSimplePara elsevierViewall">Patient characteristics&#46;</p>"
        ]
      ]
      7 => array:7 [
        "identificador" => "tbl2"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="tfn3" class="elsevierStyleSimplePara elsevierViewall">No&#46;&#58; number of patients&#59; LCR&#58; local control rate&#59; OS&#58; overall survival&#59; DSS&#58; disease-specific survival&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Stage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">No&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">LCR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">OS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">DSS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Late toxicity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">I</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">100&#37; &#40;5&#47;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">80&#46;0&#37; &#40;4&#47;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">100&#37; &#40;5&#47;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">0&#37; &#40;0&#47;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">II</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">22&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">81&#46;8&#37; &#40;18&#47;22&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">54&#46;5&#37; &#40;12&#47;22&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">54&#46;5&#37; &#40;12&#47;22&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">18&#46;2&#37; &#40;4&#47;22&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">III</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">50&#46;0&#37; &#40;2&#47;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">0&#37; &#40;0&#47;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">0&#37; &#40;0&#47;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">0&#37; &#40;0&#47;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">Total</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">80&#46;6&#37; &#40;25&#47;31&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">51&#46;6&#37; &#40;16&#47;31&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">54&#46;8&#37; &#40;17&#47;31&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">12&#46;9&#37; &#40;4&#47;31&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">X<span class="elsevierStyleSup">2</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">3&#46;026&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">5&#46;510&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">8&#46;496&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">0&#46;961&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleItalic">P</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">0&#46;066&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">0&#46;037&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">0&#46;004&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">0&#46;378&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara80" class="elsevierStyleSimplePara elsevierViewall">Outcomes of endometrial cancer treated via <span class="elsevierStyleSup">252</span>Cf neutron intracavitary brachytherapy&#46;</p>"
        ]
      ]
      8 => array:7 [
        "identificador" => "tbl3"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="tfn4" class="elsevierStyleSimplePara elsevierViewall">SE&#58; standard error&#59; CI&#58; confidential interval&#46;</p><p id="tfn5" class="elsevierStyleSimplePara elsevierViewall">Mean overall survival duration&#61;61&#46;8&#177;5&#46;2 months &#40;95&#37; confidence interval&#44; 5&#8211;85 months&#41;&#44; X<span class="elsevierStyleSup">2</span>&#61;31&#46;0&#44; and <span class="elsevierStyleItalic">p</span>&#61;0&#46;000&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">FIGO stage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Mean&#177;SE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">95&#37; CI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Median&#177;SE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">95&#37; CI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">I</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">72&#46;0&#177;2&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&#40;66&#46;7&#44;77&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">II</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">66&#46;5&#177;5&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&#40;56&#46;0&#44;77&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">85&#46;0&#177;13&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&#40;59&#46;4&#44; 110&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">III</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">15&#46;3&#177;6&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&#40;3&#46;50&#44; 27&#46;0&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">6&#46;00&#177;7&#46;50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&#40;0&#46;00&#44; 20&#46;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top"><span class="elsevierStyleBold">Total</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">61&#46;8&#177;5&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&#40;51&#46;6&#44; 72&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">73&#46;0&#177;6&#46;79&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&#40;59&#46;9&#44; 86&#46;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara90" class="elsevierStyleSimplePara elsevierViewall">Overall survival duration of endometrial cancer patients receiving <span class="elsevierStyleSup">252</span>Cf neutron intracavitary brachytherapy&#46;</p>"
        ]
      ]
      9 => array:7 [
        "identificador" => "tbl4"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="tfn6" class="elsevierStyleSimplePara elsevierViewall">COPD&#58; chronic obstructive pulmonary disease&#59; SLE&#58; systemic lupus erythematosus&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Site&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Number&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Morphology&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Number&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Comorbid diseases&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Number&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Local recurrence alone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">4 &#40;12&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Adenocarcinoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">4 &#40;12&#46;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Hypertension Diabetes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">2 &#40;6&#46;4&#37;&#41; 2 &#40;6&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Pelvic lymph node&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">3 &#40;9&#46;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Adenocarcinoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">3 &#40;9&#46;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Diabetes COPD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">2 &#40;6&#46;4&#37;&#41; 1 &#40;3&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Persistent&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">2 &#40;6&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Adenocarcinoma Clear cell carcinoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">1 &#40;3&#46;2&#37;&#41; 1 &#40;3&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Diabetes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">2 &#40;6&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Distant&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">5 &#40;16&#46;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Lung&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">2 &#40;6&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Adenocarcinoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">2 &#40;6&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Hypertension Diabetes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">1 &#40;3&#46;2&#37;&#41; 1 &#40;3&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Multi-organ&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">2 &#40;6&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Adenocarcinoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">2 &#40;6&#46;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Hypertension SLE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">1 &#40;3&#46;2&#37;&#41; 1 &#40;3&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Bone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">1 &#40;3&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Adenocarcinoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">1 &#40;3&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Diabetes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">1 &#40;3&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara100" class="elsevierStyleSimplePara elsevierViewall">The relationships of morphology and comorbid diseases with metastasis development and disease recurrence&#46;</p>"
        ]
      ]
      10 => array:7 [
        "identificador" => "tbl5"
        "etiqueta" => "Table 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Site&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="top" scope="col">Number of grade II complications &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Cystitis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">3 &#40;9&#46;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Rectum&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="top">1 &#40;3&#46;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara110" class="elsevierStyleSimplePara elsevierViewall">Late toxicity&#46;</p>"
        ]
      ]
      11 => array:7 [
        "identificador" => "tbl6"
        "etiqueta" => "Table 6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="tfn7" class="elsevierStyleSimplePara elsevierViewall">OS&#58; overall survival&#59; LDRB&#58; low-dose-rate brachytherapy&#59; HDRB&#58; high-dose-rate brachytherapy&#59; EBRT&#58; external beam radiation therapy&#59; NBT&#58; neutron brachytherapy&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">Authors&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">Method&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">Number&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">Stage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">Applicator&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">Local recurrence &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">OS &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">Late toxicity &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Inciura&#44; et al&#46; &#40;16&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">HDRB &#43;&#47;- EBRT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">29&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">I&#8211;III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Three-channel&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">17&#46;2 &#40;4&#47;29&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">48&#46;3 &#40;5 y&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">13&#46;8 &#40;4&#47;29&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Rouanet&#44; et al&#46; &#40;24&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">LDRB &#43;&#47;- EBRT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">147&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">I&#8211;III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="top">&#8212;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">24 &#40;36&#47;147&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">58&#46;4 &#40;5 y&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">11&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Knocke&#44; et al&#46; &#40;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">HDRB &#43;&#47;- EBRT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">280&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">I&#8211;III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">One-channel&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">22&#46;9 &#40;64&#47;280&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">52&#46;7 &#40;5 y&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">23&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Churn and Jone &#40;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">HDRB &#43;&#47;- EBRT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">I-II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="top">One-channel</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="top">16 &#40;6&#47;37&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">68&#46;4 &#40;5 y&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="center" valign="top">&#8212;</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">III&#8211;IV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">33 &#40;5 y&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Current study&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">NBT &#43;&#47;- EBRT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">I&#8211;III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">Two-channel&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">19&#46;4 &#40;6&#47;31&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">51&#46;6 &#40;5 y&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="top">12&#46;9 &#40;4&#47;31&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spara120" class="elsevierStyleSimplePara elsevierViewall">Literature review of the outcomes of inoperable stage I-IV endometrial cancer patients receiving radiotherapy&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "REFERENCES"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "cebibsec10"
          "bibliografiaReferencia" => array:24 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cancer statistics&#44; 2014"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => """
                              R Siegel \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              J Ma \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              Z Zou \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              A Jemal \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.3322/caac.21208"
                      "Revista" => array:7 [
                        "tituloSerie" => "CA Cancer J Clin"
                        "fecha" => "2014"
                        "volumen" => "64"
                        "numero" => "1"
                        "paginaInicial" => "9"
                        "paginaFinal" => "29"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24399786"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.3322/caac.21208"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;3322&#47;caac&#46;21208"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Report of cancer incidence and mortality in China&#44; 2010"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => """
                              W Chen \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              R Zheng \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              S Zhang \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              P Zhao \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              H Zeng \n
                              \t\t\t\t\t\t\t\t
                              """
                            5 => """
                              X Zou \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3978/j.issn.2305-5839.2014.04.05"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Transl Med"
                        "fecha" => "2014"
                        "volumen" => "2"
                        "numero" => "7"
                        "paginaInicial" => "61"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25333036"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "High Dose Rate Versus Low Dose Rate Brachytherapy for Gynecological Cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => """
                              CG Orton \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1053/SRAO00300232"
                      "Revista" => array:7 [
                        "tituloSerie" => "Semin Radiat Oncol"
                        "fecha" => "1993"
                        "volumen" => "3"
                        "numero" => "4"
                        "paginaInicial" => "232"
                        "paginaFinal" => "239"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10717075"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1053/SRAO00300232"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1016&#47;S1053-4296&#40;05&#41;80120-1"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biological effective dose evaluation in gynaecological brachytherapy&#58; LDR and HDR treatments&#44; dependence on radiobiological parameters&#44; and treatment optimisation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => """
                              C Bianchi \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              F Botta \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              L Conte \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              P Vanoli \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              L Cerizza \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1007/s11547-008-0291-4"
                      "Revista" => array:7 [
                        "tituloSerie" => "Radiol Med"
                        "fecha" => "2008"
                        "volumen" => "113"
                        "numero" => "7"
                        "paginaInicial" => "1068"
                        "paginaFinal" => "1078"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18618074"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1007/s11547-008-0291-4"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1007&#47;s11547-008-0291-4"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Californium-252 brachytherapy combined with external-beam radiotherapy for cervical cancer&#58; long-term treatment results"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => """
                              X Lei \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              CY Qian \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              Y Qing \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              KW Zhao \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              ZZ Yang \n
                              \t\t\t\t\t\t\t\t
                              """
                            5 => """
                              N Dai \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ijrobp.2010.08.039"
                      "Revista" => array:7 [
                        "tituloSerie" => "Int J Radiat Oncol Biol Phys"
                        "fecha" => "2011"
                        "volumen" => "81"
                        "numero" => "5"
                        "paginaInicial" => "1264"
                        "paginaFinal" => "1270"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21435797"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1016/j.ijrobp.2010.08.039"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1016&#47;j&#46;ijrobp&#46;2010&#46;08&#46;039"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Californium-252 &#40;252Cf&#41; versus conventional gamma radiation in the brachytherapy of advanced cervical carcinoma long-term treatment results of a randomized study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => """
                              T Tacev \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              B Ptackova \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              V Strnad \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00066-003-1005-4"
                      "Revista" => array:7 [
                        "tituloSerie" => "Strahlenther Onkol"
                        "fecha" => "2003"
                        "volumen" => "179"
                        "numero" => "6"
                        "paginaInicial" => "377"
                        "paginaFinal" => "384"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12789463"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical evaluation of 252Cf neutron intracavitary therapy for primary endometrial adenocarcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => """
                              Y Maruyama \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              NagellJR Van \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              J Yoneda \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              P DePriest \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              RJ Kryscio \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1002/1097-0142(19930615)71:12<3932::aid-cncr2820711222>3.0.co;2-a"
                      "Revista" => array:7 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "1993"
                        "volumen" => "71"
                        "numero" => "12"
                        "paginaInicial" => "3932"
                        "paginaFinal" => "3937"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8508359"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1002/1097-0142(19930615)71:12<3932::aid-cncr2820711222>3.0.co;2-a"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1002&#47;1097-0142&#40;19930615&#41;71&#58;12&#60;3932&#58;&#58;AID-CNCR2820711222&#62;3&#46;0&#46;CO&#59;2-A"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary radiotherapy for carcinoma of the endometrium using external beam radiotherapy and single line source brachytherapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => """
                              M Churn \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              B Jones \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1053/clon.1999.9059"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Oncol &#40;R Coll Radiol&#41;"
                        "fecha" => "1999"
                        "volumen" => "11"
                        "numero" => "4"
                        "paginaInicial" => "255"
                        "paginaFinal" => "262"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10473723"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1053/clon.1999.9059"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1053&#47;clon&#46;1999&#46;9059"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary treatment of endometrial carcinoma with high-dose-rate brachytherapy&#58; results of 12 years of experience with 280 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => """
                              TH Knocke \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              H Kucera \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              B Weidinger \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              W Holler \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              R Potter \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1016/s0360-3016(96)00486-5"
                      "Revista" => array:7 [
                        "tituloSerie" => "Int J Radiat Oncol Biol Phys"
                        "fecha" => "1997"
                        "volumen" => "37"
                        "numero" => "2"
                        "paginaInicial" => "359"
                        "paginaFinal" => "365"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9069308"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1016/s0360-3016(96)00486-5"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1016&#47;S0360-3016&#40;96&#41;00486-5"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Follow-up study of clinical effects of californium-252 neutron intracavitary radiotherapy and external beam radiotherapy in endometrial cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => """
                              X Lei \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              JL Shan \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              C Tang \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              KW Zhao \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "Zhonghua Fu Chan Ke Za Zhi"
                        "fecha" => "2007"
                        "volumen" => "42"
                        "numero" => "11"
                        "paginaInicial" => "733"
                        "paginaFinal" => "736"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18307897"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Image-guided high-dose-rate brachytherapy in inoperable endometrial cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => """
                              P Dankulchai \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              J Petsuksiri \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              Y Chansilpa \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              PJ Hoskin \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Br J Radiol"
                        "fecha" => "2014"
                        "volumen" => "87"
                        "numero" => "1039"
                      ]
                    ]
                    1 => array:1 [
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1259&#47;bjr&#46;20140018"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary radiation therapy for medically inoperable patients with endometrial carcinoma&#8211;stages I-II"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => """
                              M Varia \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              J Rosenman \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              J Halle \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              L Walton \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              J Currie \n
                              \t\t\t\t\t\t\t\t
                              """
                            5 => """
                              W Fowler \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1016/0360-3016(87)90253-7"
                      "Revista" => array:7 [
                        "tituloSerie" => "Int J Radiat Oncol Biol Phys"
                        "fecha" => "1987 Jan"
                        "volumen" => "13"
                        "numero" => "1"
                        "paginaInicial" => "11"
                        "paginaFinal" => "15"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3804805"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1016/0360-3016(87)90253-7"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1016&#47;0360-3016&#40;87&#41;90253-7"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Medically inoperable stage I adenocarcinoma of the endometrium treated with radiotherapy alone"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => """
                              PW Grigsby \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              RR Kuske \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              CA Perez \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              BJ Walz \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              MH Camel \n
                              \t\t\t\t\t\t\t\t
                              """
                            5 => """
                              MS Kao \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1016/0360-3016(87)90061-7"
                      "Revista" => array:7 [
                        "tituloSerie" => "Int J Radiat Oncol Biol Phys"
                        "fecha" => "1987"
                        "volumen" => "13"
                        "numero" => "4"
                        "paginaInicial" => "483"
                        "paginaFinal" => "488"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3558039"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1016/0360-3016(87)90061-7"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1016&#47;0360-3016&#40;87&#41;90061-7"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => """
                              H Kucera \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              TH Knocke \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              E Kucera \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              R Potter \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "Acta Obstet Gynecol Scand"
                        "fecha" => "1998"
                        "volumen" => "77"
                        "numero" => "10"
                        "paginaInicial" => "1008"
                        "paginaFinal" => "1012"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9849846"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:1 [
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1080&#47;j&#46;1600-0412&#46;1998&#46;771011&#46;x"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => """
                              DA Fishman \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              KB Roberts \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              JT Chambers \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              EI Kohorn \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              PE Schwartz \n
                              \t\t\t\t\t\t\t\t
                              """
                            5 => """
                              SK Chambers \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1006/gyno.1996.0123"
                      "Revista" => array:7 [
                        "tituloSerie" => "Gynecol Oncol"
                        "fecha" => "1996"
                        "volumen" => "61"
                        "numero" => "2"
                        "paginaInicial" => "189"
                        "paginaFinal" => "196"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8626131"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1006/gyno.1996.0123"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1006&#47;gyno&#46;1996&#46;0123"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term results of high-dose-rate brachytherapy and external-beam radiotherapy in the primary treatment of endometrial cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => """
                              A Inciura \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              V Atkocius \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              E Juozaityte \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              D Vaitkiene \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1269/jrr.10080"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Radiat Res"
                        "fecha" => "2010"
                        "volumen" => "51"
                        "numero" => "6"
                        "paginaInicial" => "675"
                        "paginaFinal" => "681"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21116100"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1269/jrr.10080"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1269&#47;jrr&#46;10080"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Results of treatment in locally advanced carcinoma of the endometrium"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:9 [
                            0 => """
                              K Ahmad \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              YH Kim \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              G Deppe \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              J Malone \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              A Herskovic \n
                              \t\t\t\t\t\t\t\t
                              """
                            5 => """
                              V Ratanatharathorn \n
                              \t\t\t\t\t\t\t\t
                              """
                            6 => """
                              WA Sakr \n
                              \t\t\t\t\t\t\t\t
                              """
                            7 => """
                              A Medina \n
                              \t\t\t\t\t\t\t\t
                              """
                            8 => """
                              V Malviya \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.3109/02841869009126546"
                      "Revista" => array:7 [
                        "tituloSerie" => "Acta Oncol"
                        "fecha" => "1990"
                        "volumen" => "29"
                        "numero" => "2"
                        "paginaInicial" => "203"
                        "paginaFinal" => "209"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2185804"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.3109/02841869009126546"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;3109&#47;02841869009126546"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inoperable adenocarcinoma of endometrium&#58; radiation therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:7 [
                            0 => """
                              ML Wang \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              DH Hussey \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              AP Vigliotti \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              J Benda \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              BC Wen \n
                              \t\t\t\t\t\t\t\t
                              """
                            5 => """
                              JF Doornbos \n
                              \t\t\t\t\t\t\t\t
                              """
                            6 => """
                              B Anderson \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1148/radiology.165.2.3659385"
                      "Revista" => array:7 [
                        "tituloSerie" => "Radiology"
                        "fecha" => "1987"
                        "volumen" => "165"
                        "numero" => "2"
                        "paginaInicial" => "561"
                        "paginaFinal" => "565"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3659385"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1148/radiology.165.2.3659385"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1148&#47;radiology&#46;165&#46;2&#46;3659385"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary radiation therapy for endometrial carcinoma&#58; a case controlled study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => """
                              PG Rose \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              S Baker \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              M Kern \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              TJ Fitzgerald \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              WK Tak \n
                              \t\t\t\t\t\t\t\t
                              """
                            5 => """
                              Fr Reale \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1016/0360-3016(93)90383-7"
                      "Revista" => array:7 [
                        "tituloSerie" => "Int J Radiat Oncol Biol Phys"
                        "fecha" => "1993"
                        "volumen" => "27"
                        "numero" => "3"
                        "paginaInicial" => "585"
                        "paginaFinal" => "590"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8226152"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1016/0360-3016(93)90383-7"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1016&#47;0360-3016&#40;93&#41;90383-7"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Dosimetric considerations in the treatment of inoperable endometrial carcinoma by a high dose rate afterloading packing technique"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => """
                              MG Bond \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              G Workman \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              J Martland \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              JE Clinkard \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              BM Carey \n
                              \t\t\t\t\t\t\t\t
                              """
                            5 => """
                              RI Rothwell \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1016/s0936-6555(97)80060-x"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Oncol &#40;R Coll Radiol&#41;"
                        "fecha" => "1997"
                        "volumen" => "9"
                        "numero" => "1"
                        "paginaInicial" => "41"
                        "paginaFinal" => "47"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9039813"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1016/s0936-6555(97)80060-x"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1016&#47;S0936-6555&#40;97&#41;80060-X"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "High-dose-rate Rotte &#34;Y&#34; applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer&#58; 10-year results"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => """
                              D Coon \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              S Beriwal \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              DE Heron \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              JL Kelley \n
                              \t\t\t\t\t\t\t\t
                              """
                            4 => """
                              RP Edwards \n
                              \t\t\t\t\t\t\t\t
                              """
                            5 => """
                              P Sukumvanich \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ijrobp.2007.10.026"
                      "Revista" => array:7 [
                        "tituloSerie" => "Int J Radiat Oncol Biol Phys"
                        "fecha" => "2008"
                        "volumen" => "71"
                        "numero" => "3"
                        "paginaInicial" => "779"
                        "paginaFinal" => "783"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18258388"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1016/j.ijrobp.2007.10.026"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1016&#47;j&#46;ijrobp&#46;2007&#46;10&#46;026"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => """
                              TV Nguyen \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              DG Petereit \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1006/gyno.1998.5148"
                      "Revista" => array:7 [
                        "tituloSerie" => "Gynecol Oncol"
                        "fecha" => "1998"
                        "volumen" => "71"
                        "numero" => "2"
                        "paginaInicial" => "196"
                        "paginaFinal" => "203"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9826460"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1006/gyno.1998.5148"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1006&#47;gyno&#46;1998&#46;5148"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparison of 2D vs&#46; 3D dosimetry for Rotte &#39;Y&#39; applicator high dose rate brachytherapy for medically inoperable endometrial cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => """
                              S Beriwal \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              H Kim \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              DE Heron \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              R Selvaraj \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1177/153303460600500509"
                      "Revista" => array:7 [
                        "tituloSerie" => "Technol Cancer Res Treat"
                        "fecha" => "2006"
                        "volumen" => "5"
                        "numero" => "5"
                        "paginaInicial" => "521"
                        "paginaFinal" => "527"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16981795"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1177/153303460600500509"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1177&#47;153303460600500509"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Exclusive radiation therapy in endometrial carcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => """
                              P Rouanet \n
                              \t\t\t\t\t\t\t\t
                              """
                            1 => """
                              JB Dubois \n
                              \t\t\t\t\t\t\t\t
                              """
                            2 => """
                              S Gely \n
                              \t\t\t\t\t\t\t\t
                              """
                            3 => """
                              H Pourquier \n
                              \t\t\t\t\t\t\t\t
                              """
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.1016/0360-3016(93)90201-6"
                      "Revista" => array:7 [
                        "tituloSerie" => "Int J Radiat Oncol Biol Phys"
                        "fecha" => "1993"
                        "volumen" => "26"
                        "numero" => "2"
                        "paginaInicial" => "223"
                        "paginaFinal" => "228"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8491680"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.1016/0360-3016(93)90201-6"
                      "WWW" => array:1 [
                        "link" => "http&#58;&#47;&#47;dx&#46;doi&#46;org&#47;10&#46;1016&#47;0360-3016&#40;93&#41;90201-6"
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack638157"
        "titulo" => "ACKNOWLEDGMENTS"
        "texto" => "<p id="para270" class="elsevierStylePara elsevierViewall">We first thank the patients and their families&#46; We also thank the Departments of Obstetrics and Gynecology and of Pathology and the Imaging Center of Daping Hospital&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/18075932/0000007100000001/v1_202211290914/S1807593222012960/v1_202211290914/en/main.assets"
  "Apartado" => null
  "PDF" => "https://static.elsevier.es/multimedia/18075932/0000007100000001/v1_202211290914/S1807593222012960/v1_202211290914/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222012960?idApp=UINPBA00004N"
]

Article information

ISSN: 18075932
Original language: English

DOI:10.6061/clinics/2016(01)03

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	2	0	2
2024 October	23	25	48
2024 September	23	18	41
2024 August	22	24	46
2024 July	12	28	40
2024 June	20	4	24
2024 May	10	10	20
2024 April	29	10	39
2024 March	32	8	40
2024 February	10	6	16
2024 January	14	7	21
2023 December	7	17	24
2023 November	9	12	21
2023 October	11	18	29
2023 September	7	14	21
2023 August	4	1	5
2023 July	7	8	15
2023 June	11	1	12
2023 May	33	0	33
2023 April	38	2	40
2023 March	45	1	46
2023 February	28	1	29
2023 January	17	2	19
2022 December	6	2	8
2022 November	2	0	2

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter